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5rapid developments in this field and scientific evidence on 
the risks posed by these substances. The EMCDDA 
participated in many development activities in 2012 in 
support of the efforts in this field, the most notable of which 
are described in the body of this report.
Headline activities in 2012
•  73 new psychoactive substances were officially notified 
for the first time through the EU Early warning system 
(EWS) in 2012, up from 49 in 2011, 41 in 2010 and 24 in 
2009.
•  A Joint report was produced and a risk assessment 
conducted on 4-methylamphetamine (4-MA) after 21 
deaths in total were reported by four Member States. The 
substance will now be subjected to control measures 
throughout the EU.
•  A Joint report was produced on 5-(2-aminopropyl)indole 
(5-IT) after 21 deaths were reported by three Member 
States over a short period of time. The substance will be 
risk-assessed by the Scientific Committee of the 
EMCDDA in April 2013.
•  693 Internet shops were identified by the EMCDDA 
selling ‘legal highs’ to consumers in the EU in 2012. This 
compares to 314 shops identified in January 2011 and 
170 in January 2010.
As highlighted in the first joint EMCDDA and Europol 
strategic analysis of the drug market in the EU (4), 73 new 
psychoactive substances were officially notified for the first 
time in 2012 through the EU Early warning system (EWS), 
the information exchange mechanism that was set up by 
the Council Decision. This is the largest number of 
substances ever reported in a single year, considerably up 
from the 49 substances reported in 2011, 41 in 2010 and 
This report presents the activities implemented by the 
EMCDDA and Europol in 2012 in support of Council 
Decision 2005/387/JHA on the information exchange, risk 
assessment and control of new psychoactive substances 
(hereinafter referred to as the Council Decision) (1).
This year was particularly busy for those involved in 
detecting, monitoring and responding to new psychoactive 
substances across the European Union (EU) (2). The 
unprecedented growth in the number, type and availability 
of new drugs over the past few years has also seen the 
phenomenon take on global significance. The reasons for 
the growth in this market include the increasing complexity 
and volatility of the drugs market set against a backdrop of 
globalisation and technological advancement. The rapid 
appearance of non-controlled alternatives to controlled 
drugs underlines the ability of the market to respond to 
changes in the legal status of psychoactive substances. In 
addition, an important development has been the growing 
interaction between the illicit and ‘legal highs’ markets, 
whereby some substances are legally sourced and either 
sold directly on the illicit market or turned into products and 
sold as ‘legal highs’. It is well established that organised 
crime is involved in some of these activities and continues 
to exploit the opportunities presented by the market in new 
drugs. 
New psychoactive substances, particularly the so-called 
‘legal highs’, continued to be a high policy priority in the EU 
and many Member States. This was evidenced by 
responses at national level including awareness raising, 
new legislative measures, and the inclusion of new 
psychoactive substances in general population surveys. As 
announced in the communication ‘Towards a stronger 
European response to drugs’ (3), the European Commission 
is currently preparing and will propose new EU legislation 
on new psychoactive substances taking into account the 
Overview
(1)  Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances, 
OJ L 127, 20.5.2005, p. 32.
(2) This report uses the terms ‘new psychoactive substances’ and ‘new drugs’ interchangeably.
(3)  European Commission (2011), Communication from the Commission to the European Parliament and the Council, Towards a stronger 
European response to drugs, Brussels, 25.10.11, COM(2011) 689/2.
(4) EMCDDA and Europol (2013), EU drug markets report: a strategic analysis, Publications Office of the European Union, Luxembourg.
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detections were either alone or in combination with other 
substances, in particular amphetamine. The report also 
described how 4-MA could have serious adverse effects, 
such as hyperthermia, hypertension, anorexia, nausea, 
headache, insomnia, paranoia and anxiety. Fourteen 
European countries provided data on seizures of the drug 
where it had been sold as amphetamine and frequently 
mixed with it. 4-MA has no established medical value or 
known legitimate purpose, aside from limited use in 
scientific research and as an analytical reference standard.
The Joint report on 5-IT (8) was produced after the 
substance was considered by the EMCDDA and Europol to 
be causing significant concern in several EU Member 
States. It was first detected in Norway in April 2012, and 
subsequently by authorities in seven countries. It was 
associated with 21 deaths in three Member States 
(Hungary, Sweden, and the United Kingdom). As a result of 
the report, the Council of the European Union requested 
that the EMCDDA conduct a formal risk assessment on the 
substance, which is planned for April 2013.
24 in 2009. The list of new substances notified in 2012 was 
dominated by 30 synthetic cannabinoids (5) and 19 
compounds classed as ‘others’ which do not conform to the 
main categories currently used by the EMCDDA. Together, 
these two groups represented about two-thirds of the total 
number of substances reported in 2012 (Annex 1 and 
Annex 2). Overall, the number of substances notified in the 
last two years accounts for more than half of the total 
number of substances notified under the terms of the 
Council Decision since May 2005.
In 2012, the EMCDDA and Europol produced two Joint 
reports on the new psychoactive substances 4-MA and 
5-IT, in accordance with Article 5 of the Council Decision. 
The findings are summarised in this report. 
The Joint report on 4-MA (6) led to a formal risk assessment 
that was conducted in November by the extended Scientific 
Committee of the EMCDDA. The risk assessment report 
detailed 21 deaths in four Member States (Belgium, 
Denmark, Netherlands, and the United Kingdom), where 
4-MA was detected in post-mortem samples (7). These 
(5)  A more precise term for these compounds is ‘synthetic cannabinoid receptor agonists’, however, the term ‘synthetic cannabinoids’ has been 
widely accepted and is therefore used throughout the report.
(6)  EMCDDA and Europol (2012), EMCDDA–Europol joint report on a new psychoactive substance, 4-methylamphetamine, EMCDDA, Lisbon. 
Available at: http://www.emcdda.europa.eu/attachements.cfm/att_191982_EN_TDAS12001ENN.PDF
(7)  Council of the European Union (2012), Risk assessment report on the new psychoactive substance 4-methylamphetamine, 17275/12 
CORDROGUE 98 SAN 320. Available at: http://register.consilium.europa.eu/pdf/en/12/st17/st17275.en12.pdf
(8)  EMCDDA and Europol (2012), EMCDDA–Europol joint report on a new psychoactive substance, 5-(2-aminopropyl)indole, EMCDDA, Lisbon. 
Available at: http://www.emcdda.europa.eu/publications/joint-reports/5-IT
7To ensure transparency in the implementation of the 
Council Decision, Article 10 stipulates that: ‘The EMCDDA 
and Europol shall report annually to the European 
Parliament, the Council and the Commission on the 
implementation of this Decision. The report will take into 
account all aspects required for an assessment of the 
efficacy and achievements of the system created by this 
Decision. The report shall, in particular, include experience 
relating to coordination between the system set out in this 
Decision and the Pharmacovigilance system’.
In compliance with Article 10, the EMCDDA and Europol 
herewith present the eighth such Annual Report on the 
implementation of the Council Decision, covering the period 
January to December 2012. The report outlines the results 
of the implementation, describes key issues arising from 
accumulated experiences, and also serves as a monitoring 
tool. In order to facilitate the reading of the report, the 
reader is referred to the full text of the Council Decision 
(Appendix).
The report is written as a standalone document with 
annexes kept to a minimum (11). Annex 1 provides the list of 
new psychoactive substances notified in 2012. This 
includes the systematic chemical name, the reporting 
country, and date of notification for each substance. 
Comprehensive information on the new substances 
described in the report is available from the EMCDDA and 
Europol. Annex 2 provides a list of those new substances 
notified in 2012 categorised as ‘others’. Annex 3 provides 
the legal and working definitions used by the EMCDDA to 
classify and describe new drugs. The reader should note 
that these definitions were further developed during 2012 
to reflect changes in the phenomenon. Finally, Annex 4 
provides an overview of the main groups of new 
psychoactive substances monitored by the EWS and their 
molecular characteristics.
As part of the response to new psychoactive substances 
within the EU, the Council Decision 2005/387/JHA of 10 
May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances established a 
mechanism for the rapid exchange of information on 
substances that may pose public health and social threats, 
including the involvement of organised crime (Box 1). This 
provides a legal basis for EU institutions and Member 
States to monitor all new narcotic and psychotropic 
substances that appear on the European drug scene (9). 
Where necessary, the Council Decision also provides for an 
assessment of the risks associated with these new 
substances, so that control measures deriving from 
Member States’ obligations to the United Nations 
international drug control conventions (10) can also be 
applied to new psychoactive substances. 
The EMCDDA and Europol, in close collaboration with their 
respective expert networks, the Reitox national focal points 
and Europol National Units, are assigned a central role in 
detecting, notifying and monitoring new psychoactive 
substances (Article 4 of the Council Decision). Furthermore, 
where necessary, and in cooperation with the European 
Medicines Agency (EMA), the two organisations may 
collect, analyse and present information on a new 
psychoactive substance in the form of a Joint report (Article 
5). The Joint report provides evidence to the Council of the 
European Union and the European Commission on the 
need to request a risk assessment on a new psychoactive 
substance. Such a risk assessment examines the health 
and social risks posed by: the use of, manufacture of, and, 
traffic in, a new psychoactive substance; the involvement of 
organised crime; and, the possible consequences of control 
measures. In order to conduct the risk assessment, the 
EMCDDA convenes a special meeting under the auspices 
of its Scientific Committee, extended with additional 
experts as necessary (Article 6).
1. Introduction and background
(9)1 See definitions in Annex 3.
(10) The 1961 United Nations Single Convention on Narcotic Drugs and the 1971 United Nations Convention on Psychotropic Substances.
(11)  Where possible, the report avoids the use of overly technical discussion and language, however, this is occasionally unavoidable given the 
nature of the phenomenon.
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New drugs in Europe at a glance
The EMCDDA and Europol have played a central role in the 
detection, monitoring and assessment of new drugs in Europe 
since 1997. During this time, the new drug phenomenon has 
evolved to become one of the most important contemporary 
developments in the drugs field, with the past few years seeing 
unprecedented growth in their number, type and availability.
•  The EU Early warning system (EWS) operated by the 
EMCDDA and Europol currently monitors more than 280 
new psychoactive substances.
•  73 new psychoactive substances were officially notified for 
the first time in the EU through the EWS in 2012, up from 49 
in 2011, 41 in 2010 and 24 in 2009.
•  Since 1997, 13 substances have been risk-assessed. Of 
these, eight (4-MTA, PMMA, 2C-I, 2C-T-2, 2-C-T-7, TMA-2, 
BZP, mephedrone) are now controlled across the EU and one 
(GHB) is controlled at international level. 
4-Methylamphetamine (4-MA) is in the process of being 
subjected to control measures across the EU.
•  The main groups of substances monitored by the EWS are: 
phenethylamines (with stimulant, entactogenic or 
hallucinogenic effects, such as PMMA and 2C-I); tryptamines 
(which have predominantly hallucinogenic effects, such as 
AMT and 5-MeO-DALT); piperazines (which exhibit 
predominantly stimulant effects, such as mCPP and BZP); 
cathinones (such as mephedrone, methylone and MDPV, 
which exhibit stimulant effects); synthetic cannabinoids 
(which can have hallucinogenic and depressant effects); and, 
a broad group of substances that do not strictly belong to 
any of the previous groups.
•  The Internet appears to be playing a growing role in shaping 
the market in new drugs. 693 Internet shops selling ‘legal 
highs’ to EU consumers were identified by EMCDDA 
monitoring in 2012. This compares to 314 shops identified in 
January 2011 and 170 in January 2010.
•  A 2011 Eurobarometer survey of young people aged 15–24 
from across the EU found that while lifetime use of ‘legal 
highs’ in most Member States was 5 % or less, use in the 
United Kingdom, Latvia, Poland and Ireland was 8 %, 9 %, 
9 % and 16 % respectively.
Further information on new drugs can be found at:  
www.emcdda.europa.eu/activities/action-on-new-drugs
9collect national risk assessments on new psychoactive 
substances on a routine basis, and has made them 
available on the EDND in order to help inform policy 
responses in the Member States.
Also in 2012, the EMCDDA published a compendium 
providing a comprehensive overview of the 30 national early 
warning systems that participate in the EWS network (13). 
The publication aims to promote best practice and enhance 
the exchange of experiences from the national level. 
Furthermore, the document also serves to assist third 
parties who may be considering implementing an early 
warning system — a common enquiry to the EMCDDA from 
countries outside the EWS network. The document is 
available on the EMCDDA website (14).
The EMCDDA is in the process of preparing to provide 
assistance in the form of training on the EWS in the context 
of the project for Pre-Accession Assistance (IPA) 
beneficiaries (15) in Prague in April 2013.
2.1.2.  Annual meeting of the Reitox EWS network
The 12th Annual meeting of the Reitox Early warning 
system network was held in Lisbon on 24–25 May 2012. 
Participants included representatives from the 27 EU 
Member States, Croatia, Turkey and Norway. The two 
candidate countries Serbia and the former Yugoslav 
Republic of Macedonia and the potential candidate 
countries Albania and Kosovo (16) were also represented. 
Europol was also represented. Invited expert speakers 
attended from Finland, the United Kingdom and the United 
States of America. The meeting was split into the following 
sessions:
2.1.  Specific implementation arrangements
2.1.1.  Assistance to national early warning systems 
The Action on new drugs team within the EMCDDA regularly 
provides support to the national early warning systems 
within the national focal points in order to assist them in the 
identification of new substances. In addition, other requests 
for assistance related to the new drug phenomenon are 
regularly received from the Member States, EU agencies 
and other institutions, individual experts, third countries 
and the media. In order to ensure an effective and efficient 
response to this growing number of requests, the EMCDDA 
has established a rapid response team. 
Building on improvements developed over the past few 
years, 2012 saw the routine exchange of instrumental 
analytical data such as GC-MS, FT-IR and NMR (12) spectra 
for the 73 new substances that were notified. These data, 
along with additional analytical data from substances already 
reported, were also included in the substance profiles on the 
European Database on New Drugs (EDND). By providing the 
data in common formats, laboratories are then able to import 
them directly into their instruments. In this way, laboratories 
across Europe can ensure that their analytical libraries are 
up-to-date, thus improving the capacity and speed in which 
new substances can be detected. This approach is becoming 
of growing importance to laboratories as the chemistry of 
new drugs becomes increasingly complex, and more 
advanced analytical techniques are often needed to 
elucidate their molecular structure. 
While provision of analytical data plays a key role in 
identifying new drugs, the EMCDDA has also begun to 
(12)  Gas chromatography–mass spectrometry, Fourier transform-infrared spectrometry and nuclear magnetic resonance spectrometry are some 
of the typical analytical techniques used to identify new psychoactive substances.
(13) The 27 EU Member States, Croatia, Turkey and Norway.
(14)  EMCDDA (2012), Early warning system — national profiles, EMCDDA, Lisbon. Available at: http://www.emcdda.europa.eu/thematic-papers/
ews
(15)  Participating countries: Albania, Bosnia and Herzegovina, Serbia, Montenegro, the Former Yugoslav Republic of Macedonia, Kosovo (this 
designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of 
independance), Turkey and Croatia.
(16)  This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of 
independence.
2.  Implementation arrangements and cooperation with the 
EU Pharmacovigilance system
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A presentation from Cambridge University described how 
computational methods can be used to predict the 
potential properties of new substances, including their 
toxicity and psychoactivity (section 4.4). A guest speaker 
from the Addiction Research Institute at Austin University, 
Texas provided an overview of drug trends and use patterns 
in the United States (US). Of particular note in this 
presentation was the recent increase in reports of exposure 
to synthetic cannabinoids and synthetic cathinones to 
public health agencies.
2.1.3.  Structured monitoring of the Internet — online 
availability of ‘legal highs’ 
Part of the reason for the growth in the availability of new 
drugs over the past few years is due to the sophisticated 
ways in which drugs such as the so-called ‘legal highs’ can 
now be marketed and distributed. This includes advertising 
and selling them on an open market, including through 
online shops and in ‘bricks and mortar’ head shops. In order 
to monitor the online market and to get a better 
understanding of how this affects the availability of new 
drugs, the EMCDDA has conducted multilingual snapshots 
since 2006. The snapshots function as a rapid assessment 
of the market and are undertaken during a limited time 
window. Information collected in these snapshots can 
provide insights into the market characteristics, including:
•  the number of online shops offering to sell new drugs to 
consumers in at least one EU Member State and, for 
these shops:
•  the names and prices of the substances and products 
that are offered for sale;
•  the marketing and distribution techniques used; 
•  the number of businesses in a particular geographical 
area; and, 
•  the detection of new drugs that have not yet been 
identified through chemical analysis of seizures, test 
purchases or biological samples. 
In 2012, a snapshot was conducted in 20 EU languages, as 
well as Norwegian, Russian and Ukrainian. Along with other 
key information on this market, the snapshot identified 693 
shops selling ‘legal high’ type products. This compares to 
314 shops identified in January 2011 and 170 in January 
2010 (19). Targeted Internet searches were also conducted 
•  the implementation of the Council Decision;
•  updates from the national EWS correspondents;
•  mephedrone, the continuation: promises and pitfalls;
•  new approaches for monitoring new drugs and trends in 
drug use; and,
•  controlling new psychoactive substances.
During the sessions, delegates heard about the recent 
experiences of the Member States and were updated on 
the developments in the field. Relevant highlights are 
provided below.
The Belgian national focal point provided an overview of 
their experience with 4-MA, which was associated with a 
cluster of deaths that occurred over a short period of time. 
A formal information request under Article 5.1 of the 
Council Decision was launched during the meeting in order 
to provide further information for the Joint report. Details of 
the Joint report and risk assessment of 4-MA are provided 
in Sections 3.2.1 and 3.2.2, respectively. 
The Hungarian national focal point provided an overview of 
a two-day workshop on ‘Exchange on data collection 
challenges related to new psychoactive substances use’, 
which took place in Budapest in April 2012. 
Representatives from 10 Member States and the EMCDDA 
attended. A summary of the workshop is available on the 
Hungarian national focal point website (17). The national 
focal point also provided an update on the amendments to 
Hungarian legislation concerning new psychoactive 
substances. The amendments introduced a new schedule, 
which includes a list of named substances and four distinct 
generic definitions for synthetic cannabinoids, cathinones, 
tryptamines and phenethylamines.
The EMA provided an update on the cooperation with the 
EMCDDA, in particular in relation to the EU 
Pharmacovigilance system.
Experts from the United Kingdom and Finland discussed 
two novel approaches for monitoring for new psychoactive 
substances and their metabolites in human waste products. 
These pioneering methods are being actively supported by 
the EMCDDA and will be closely monitored and developed 
in the coming years. More information on this can be found 
in section 4.3 and on the EMCDDA website (18). 
(17)  Hungarian national focal point (2012), Exchange on data collection challenges related to new psychoactive substances use, Hungarian 
national focal point, Budapest. Available at: http://drogfokuszpont.hu/wp-content/uploads/workshop_summary_final.pdf
(18) http://www.emcdda.europa.eu/wastewater-analysis
(19)  EMCDDA (2011), Online sales of new psychoactive substances/’legal highs’: summary of results from the 2011 multilingual snapshots, 
EMCDDA, Lisbon. Available at: http://www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot
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emerging psychoactive substances in Palm Springs, US. 
The event gathered over 300 participants from 72 
countries. Building on the First international 
multidisciplinary forum on new drugs that was organised by 
the EMCDDA in Lisbon in May 2011, the event brought 
together leading US, European and other international 
experts to examine the issue from a global perspective. The 
EMCDDA gave one of the keynote presentations as well as 
six other presentations during the event. 
During the event, updates were provided by the EU, 
Australia, Japan, the US, as well as the United Nations 
Office on Drugs and Crime (UNODC). These presentations 
explored the appearance and use of new drugs, as well as 
how they are detected, monitored, risk-assessed and 
controlled. The updates revealed important commonalities 
between countries in the marketing and use of new drugs 
as well as the responses to this phenomenon. 
Importantly, the challenges posed by new psychoactive 
substances for prevention and treatment were also 
addressed at the event. Discussions considered individual 
substances, as well as the broader new drugs phenomenon, 
the implications for the treatment of acute toxicity and the 
prevention of use. Presentations included: insights from 
hospital emergency departments in the United Kingdom; 
prevention strategies from Poland; and, medical experts 
from the US who examined synthetic cannabinoids and 
piperazines.
Europol–EMCDDA law enforcement expert meeting on new 
psychoactive substances
In September 2012, an expert meeting on new 
psychoactive substances was held at the headquarters of 
Europol in the Hague, co-organised and co-chaired by the 
EMCDDA and Europol. This meeting was foreseen in the 
EMPACT (European Multidisciplinary Platform Against 
Criminal Threats) Operational Action Plan (OAP) for 2012 
under the priority to ‘reduce the production and distribution 
in the EU of synthetic drugs including new psychoactive 
substances’. The aim of the meeting was to raise awareness 
of new psychoactive substances as well as to improve the 
response by law enforcement, including the information 
flow to Europol. Representatives from law enforcement 
from 26 EU Member States and Norway attended.
Europol and the EMCDDA set the scene by presenting the 
EWS and an overview of the current situation in Europe. The 
European Commission presented some of the challenges 
facing EU legislators in terms of tackling the issue. A 
representative from the Belgian Federal Police provided an 
overview of the situation in Belgium. This included case 
in English in support of the EMCDDA–Europol Joint reports 
on 4-MA and 5-IT.
The methodology used for the snapshot series is currently 
being revised with support from the ICT unit at the 
EMCDDA. This work will lead to improvements in the scope, 
coverage and robustness of the methodology. Overall, 
these revisions will allow the continual monitoring of both 
the online market in new drugs and the emerging online 
market in controlled drugs.
2.1.4. Supporting activities
In support of the Council Decision, the EMCDDA regularly 
organises and participates in events and activities, often in 
collaboration with partners. These activities are designed to 
develop the EWS network and provide support to others 
working in the field of new drugs. These events and 
activities provide a platform to improve collaboration 
among EWS partners and promote areas of best practice 
where possible. Some of the most significant activities 
carried out in 2012 are described below.
First international conference on novel psychoactive 
substances
The ‘ever-changing world of psychoactive drugs’ was the 
title and focus of the First international conference on novel 
psychoactive substances. The conference was a joint 
initiative of the EU-funded Recreational Drugs European 
Network (ReDNet) project and the EMCDDA, and was held 
in Budapest in March 2012.
The aim of the conference was the exchange of scientific 
knowledge on new psychoactive substances and the 
forensic, clinical and legal challenges faced by practitioners. 
The programme was based around four key themes: clinical 
challenges; novel prevention models for novel compounds; 
legal challenges; and, substance misuse and lifestyle. 
International experts, including many partners from the 
EWS network and members of the EMCDDA Action on new 
drugs team, delivered over 60 presentations.
Building on this, a second conference will be held in 
Swansea, United Kingdom in September 2013 and will 
focus on the latest research on the effects of new drugs in 
humans.
NIDA–EMCDDA second international forum on new drugs 
In June 2012, the United States National Institute on Drug 
Abuse (NIDA) and the EMCDDA co-organised and co-
hosted the Second interdisciplinary forum on new and 
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•  Law enforcement representatives from the Member 
States would make efforts to improve information flow to 
Europol.
•  The EMPACT OAP activities for the forthcoming year 
would be updated to reflect the proposals above.
•  A follow-up meeting involving experts from EU law 
enforcement agencies will be held in 2013 at the 
EMCDDA in Lisbon.
2.2.  Cooperation with the EMA and the 
Pharmacovigilance system
The EMA is a key partner in the implementation of the 
system set up by the Council Decision. The EMCDDA and 
EMA have established protocols for bilateral exchange of 
information on the basis of data available through the EWS 
and the EU Pharmacovigilance system. The existing 
databases of the two agencies, EudraVigilance at the EMA 
and the European Database on New Drugs (EDND) at the 
EMCDDA, are used to enable reliable and rapid exchange of 
information between the two agencies. 
On 7 September 2012 in Lisbon, a revised working 
arrangement was signed by the Directors of the EMCDDA 
and EMA. The arrangement enhances cooperation between 
the two agencies, including the exchange of information on 
the abuse of medicinal products as part of the 
Pharmacovigilance system (20).
As part of the EWS, the two agencies regularly exchange 
information on new psychoactive substances, as well as ad 
hoc reports relating to the misuse of medicinal products in 
order to complement the Pharmacovigilance system (21). 
In 2012, formal consultations and exchange of information 
took place between the EMCDDA and EMA regarding 4-MA 
(section 3.2.1) and 5-IT (section 3.2.3).
studies demonstrating the scale of the phenomenon as well 
as the modus operandi of some of the groups involved in 
making ‘legal high’ products.
Europol highlighted the global nature of the challenge faced 
by law enforcement by providing an overview of a multi-
national police operation involving 12 EU Member States, 
Australia, the US and Eurojust (the EU agency responsible 
for judicial cooperation), which targeted a Chinese supplier 
involved in trafficking large quantities of new psychoactive 
substances.
There was an acknowledgement at the meeting that law 
enforcement has a particularly challenging task when 
responding to new psychoactive substances and that 
considerable effort is required to address this. There was, 
however, an equally strong message that this is an issue 
that law enforcement is willing to tackle. An area of concern 
expressed was the requirement for clear definitions for this 
area of work, which would enable law enforcement officers 
across Europe to communicate more effectively. It was also 
identified that customs authorities have a key role to play 
and therefore close collaboration by all law enforcement 
agencies is required. 
At the conclusion of the meeting it was proposed that:
•  There could be a network of law enforcement 
correspondents who would provide a point of contact for 
Europol for matters involving new psychoactive 
substances. In addition, such a network could meet to 
discuss the issues of new psychoactive substances, 
perhaps coinciding with the Reitox EWS annual meeting 
and thus taking the opportunity to develop and enhance 
the relationship with the national focal points.
•  Law enforcement representatives from the Member 
States who were unaware of their Reitox national focal 
point were encouraged to make contact with them.
(20) http://www.emcdda.europa.eu/about/partners/ema
(21)  An example of this in 2012 was the exchange of information from EudraVigilance related to the abuse of zopiclone, a medicinal product 
authorised in some Member States for the treatment of insomnia.
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data can serve to provide timely harm reduction messages 
when appropriately contextualised. 
For monitoring purposes, the EMCDDA categorises new 
psychoactive substances by the chemical family to which 
they belong. This is the case with phenethylamines, 
tryptamines, piperazines and cathinones. In the case of the 
synthetic cannabinoids, these are currently categorised on 
the basis of their mode of action rather than their chemical 
family. The remaining substances are categorised as 
miscellaneous ‘others’ (Box 2).
In 2012, the list of new substances was dominated by 30 
synthetic cannabinoids and 19 miscellaneous ‘others’. 
Together these represented two-thirds of the total number 
of substances reported in 2012 (Figure 1, Annex 1 and 
Annex 2). 
3.1.  New psychoactive substances notified 
in 2012
During 2012, a total of 73 new psychoactive substances 
were formally notified for the first time through the EWS 
(Figure 1 and Annex 1). This continues the trend of year-on-
year increases that began in 2008. In part this may be due 
to the increased detection and reporting capacities of 
Member States, arising from a growing concern about 
these substances and the need for high quality information 
by decision-makers in order to inform policy responses. The 
EMCDDA has supported these developments with the 
entire EWS network benefiting from the outputs of such 
national initiatives. These data can then be used by 
policymakers, government departments and advisory 
bodies in order to inform policy responses. In addition, such 
3. Formal activities
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Figure 1: Number of new psychoactive substances notified for the first time to the EWS since May 2005 (22)
(22)  In some previous reports, the figure used in graphical representations for the number of new psychoactive substances notified in 2007 was 
16. The correct figure, as shown above, is 15, as was reported in the EMCDDA–Europol 2007 Implementation Report. It is thought that this 
situation may have arisen as 16 new substances appeared in Annex 2 of that report. However, as noted in the report, nimetazepam (Annex 2, 
substance 12) is controlled under the 1971 United Nations Convention on Psychotropic Substances and is therefore outside of the scope of 
the Council Decision.
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well-studied synthetic cannabinoid named after John W. 
Huffman, the researcher who first synthesised and 
characterised the substance. In the case of the ‘PB-22’, two 
modifications have been made to the basic molecule to 
produce a substance with properties that can only be 
speculated. This substance was notified in December by 
the Finnish national focal point, which provided details of a 
case where 54 kilograms were intercepted by customs 
authorities. The package was sent from China, a common 
source of the bulk new psychoactive substances, and was 
en route to Russia.
3.1.2. Phenethylamines
In 2012, 14 new substituted phenethylamines were formally 
notified to the EWS. This is more than twice the number 
detected in any previous year and accounts for 
approximately one-third of all the phenethylamines 
detected since 2005. 
In previous years, the phenethylamines that have emerged 
on the new drugs market have mainly been limited to those 
described by Shulgin et al. (23). Significantly, six 
phenethylamine derivatives were notified in 2012 that 
contain a chemical group called ‘N-2-methoxybenzyl’, which 
is often abbreviated in chemistry as ‘-NBOMe’ (24). Studies 
on some of these compounds have shown that in terms of 
binding affinity these derivatives are an order of magnitude 
3.1.1. Synthetic cannabinoids
In 2012, 30 new synthetic cannabinoids were formally 
notified to the EWS. These substances make up the largest 
group of compounds monitored by the EWS, with 74 
notified since 2008. However, this group is based on mode 
of action rather than chemical family and therefore direct 
comparisons in terms of numbers should be made with 
caution.
For some of the synthetic cannabinoids that have been 
notified, there is an existing body of scientific literature 
about their chemistry, structure-activity relationships, 
potency and effects. This literature appears to be exploited 
by those involved in the trade of synthetic cannabinoids 
leading to the appearance of a growing number of new 
substances with similar core structures to the studied 
compounds but with minor chemical modifications. These 
may be attempts to circumvent drug control laws, however, 
these new substances may exhibit different chemical and 
pharmacological properties compared to the synthetic 
cannabinoids that have been studied. Indeed, frequently in 
2012, new synthetic cannabinoids were notified about 
which little could be found in the scientific literature, 
perhaps indicating a degree of experimentation on the part 
of the producer. One such example is JWH-018 
carboxylate, quinolinyl derivative (Annex 1, substance 58), 
which has been offered for sale on the Internet under the 
name ‘PB-22’. This substance is based on JWH-018, a 
Figure 2: Structure of JWH-018 and ‘PB-22’
JWH-018 ‘PB-22’
(23)  Shulgin, A., et al. (2011), The Shulgin index volume 1: psychedelic phenethylamines and related compounds, Transform Press, Berkeley.
(24) This abbreviation has provided a convenient headline for media reports regarding the dangers of so-called ‘N-bomb’ drugs.
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3.1.4. Cathinones
In 2012, five new synthetic cathinone derivatives were 
formally notified to the EWS. This compares to eight notified 
in 2011 and 15 in 2010. 
3.1.5. Piperazines
In 2012, one new piperazine was formally notified to the 
EWS. The substance, 1-(3-methylbenzyl)piperazine, is a 
derivative of benzylpiperazine (BZP) and a structural 
isomer of methylbenzylpiperazine (MBZP). This new 
substance was detected in a urine sample along with the 
synthetic cathinone derivative MDPV 
(methylenedioxypyrovalerone), which was first notified to 
the EMCDDA in 2008. Notably, only two new piperazine 
derivatives have been notified since 2008.
3.1.6. Miscellaneous ‘others’ substances 
In 2012, 19 new miscellaneous ‘other’ substances were 
formally notified to the EWS. This diverse group contains 
substances that do not fit the established EMCDDA 
categories described above. They are presented for ease of 
reference in Annex 2. Of note is the detection of several 
derivatives of controlled drugs within this category: 
•  5-APDB, 6-APDB and 5-APDI (Annex 1, refs. 15, 17 and 
54, respectively). These are mono- or di-deoxygenated 
derivatives of the stimulant drug 
methylenedioxiamphetamine (MDA);
•  thienoamphetamine (Annex 1, ref. 13) a thiophene 
analogue of amphetamine; 
•  3-MeO-PCP, 2-MeO-ketamine and N-ethylnorketamine 
(Annex 1, refs. 21, 50 and 53, respectively). These are 
derivatives of the dissociative drug phencyclidine (PCP) 
and closely related to ketamine; and,
•  (iso)butyryl fentanyl (Annex 1, ref. 63) a derivative of the 
potent synthetic opioid fentanyl.
Furthermore, it is also notable that 5-APDB, 6-APDB and 
thienoamphetamine contain only minor structural 
modifications to 5-APB, 6-APB and 
methylthienylpropamine, respectively, which were notified 
in 2011 (25). These substances are good examples of the 
rapid chemical evolution seen on the new drugs market.
The miscellaneous ‘others’ category also contains several 
substances that are medicinal products or are derivatives 
thereof: 
more potent than their parent phenethylamine compounds. 
This finding is supported by reports to the EWS detailing the 
seizure of ‘blotters’ and sugar cube dosage forms, which are 
typically used to administer drugs that are active in the 
microgram range (such as LSD).
By the end of 2012, no adverse effects had been reported 
to the EWS that were associated with these potent 
phenethylamine substances. However, media reports from 
the US and Australia suggest that their use has been 
associated with non-fatal intoxications and deaths. The 
EWS network is well-informed about the potential dangers 
posed by ‘-NBOMe’ substances and remains vigilant in light 
of this new trend. In this respect, at the time of writing this 
report (March 2013), the first reports of non-fatal 
intoxications within the EU have been made to the EWS and 
a public health warning was issued by the EMCDDA.
3.1.3. Tryptamines
In 2012, four new tryptamine derivatives were formally 
notified to the EWS. Although a small number, it is more 
than was notified in the previous three years combined. 
Three of the new tryptamine substances were detected in 
powders that were seized by the authorities in 2011. This 
illustrates that there is often a time lag between when 
samples are seized or collected and when the notifications 
are sent to the EMCDDA or Europol. 
Figure 3:  25B-NBOMe ‘blotters’ (Annex 1, Substance 66), 
Norwegian national focal point
(25)  EMCDDA and Europol (2012), EMCDDA–Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA, EMCDDA, 
Lisbon.
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•  4-fluoroephedrine: a ring-fluorinated derivative of 
ephedrine. Ephedrine is a sympathomimetic alkaloid of 
plant origin that increases the activity of noradrenaline on 
adrenergic receptors. It is used as a stimulant, a 
bronchodilator and an appetite suppressant. 
4-Fluoroephedrine can also be used as a precursor for 
the manufacture of the new psychoactive substance 
4-fluoro-N-methylamphetamine (4-FMA). This is directly 
analogous to the use of ephedrine as a precursor in the 
manufacture of N-methylamphetamine. 4-FMA was first 
notified to the EWS by Norway in March 2010;
•  4-methylaminorex p-methyl derivative: a ring-methylated 
derivative of 4-methylaminorex (‘U4Euh’, ‘Euphoria’), 
which has been reported to be a stimulant and possess 
anorectic effects similar to amphetamine. The parent drug 
‘aminorex’ was once an authorised medicinal product that 
was used as an anorectic agent. It was withdrawn in 1972 
after its use was associated with pulmonary 
hypertension; and,
•  4-methylphendimetrazine: a ring-substituted derivative of 
phendimetrazine, which is an appetite suppressant (a 
•  phenibut: a derivative of the naturally occurring inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA). 
Chemically, it has the parent structure of a 
phenethylamine. It was discovered and introduced into 
clinical practice in Russia in the 1960s for its anxiolytic 
and reported nootropic (cognition enhancing) effects. It is 
currently being sold both as a ‘dietary supplement’ and 
‘research chemical’ in a number of EU Member States;
•  zopiclone: a non-benzodiazepine hypnotic/sedative that 
belongs to the group of cyclopyrrolones (one of the 
so-called ‘Z-drugs’). It is authorised as a medicinal 
product in some Member States for the treatment of 
insomnia;
•  pyrazolam: a benzodiazepine of which apparently little is 
known. It is similar in chemical structure to alprazolam, 
which is authorised as a medicinal product in some 
Member States. However, compared to alprazolam, 
pyrazolam contains a bromine atom rather than a chlorine 
atom and contains a pyridinyl group instead of a phenyl 
group. It currently being sold as a ‘research chemical’ by 
Internet retailers;
Sub-categorisation within the ‘others’ group
The EMCDDA has grouped these substances into sub-
categories in order to convey the contents of this group in a 
meaningful, structured way. Some sub-categories are based 
on chemical family, while others are based on mode of action. 
Where the substance has a natural origin or is derived from 
medicines, these are listed separately. This is intended for 
illustration purposes only and these will not be adopted as 
official categories in the EWS.
The sub-categories are: aminocyclohexane derivatives; 
aminoindanes; arylethylamines (not being phenethylamines 
nor tryptamines); piperidines and pyrrolidines; narcotic 
analgesics; synthetic substitutes of cocaine; medicines and 
derivatives of medicines; and, plants, mushrooms and their 
extracts. The chart below shows the substances notified since 
1997 placed into these sub-categories which, despite this 
exercise, still includes eight substances which do not fit into 
any other category.
Breakdown of the miscellaneous ‘others’ category of new psychoactive substances notified between 1997 and 2012
Arylethylamines 
11
Narcotic analgesics
 4
Others
 8
Piperidines and 
pyrrolidines 
5
Plant extracts
 8
Synthetic cocaine 
substitutes
 2
Aminocyclohexane 
derivatives
 8
Aminoindanes
 4
Medicine and derivatives 
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and 5-IT, each through a Joint report based upon the 
following criteria:
1. the amount of the material seized;
2.  evidence of organised crime involvement;
3.  evidence of international trafficking;
4.  analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6.  evidence of cases of serious intoxication or fatalities.
3.2.1. 4-Methylamphetamine (4-MA) — Joint report
At the beginning of 2012, the EMCDDA and Europol agreed 
that the information collected on 4-MA satisfied all the 
above criteria. The two organisations concluded that 
sufficient information had been accumulated to merit the 
production of a Joint report as stipulated in Article 5.1 of 
the Council Decision. In compliance with the provisions of 
the Decision, on 21 May 2012 the EMCDDA and Europol 
launched a procedure for the collection of information on 
4-MA in order to prepare the Joint report. 
Key findings of the Joint report
4-MA is a ring-methylated derivative of amphetamine, and 
belongs to the group of synthetic phenethylamines. It was 
first detected in Belgium in October 2009, and was notified 
to the EMCDDA through the EWS on 14 December 2009.
Twelve EU Member States as well as Croatia and Norway 
reported seizures of 4-MA to the EMCDDA and Europol. 
These were mostly in powder or paste form, ranging in 
weight from 0.02 grams up to 147 kilograms. Samples that 
contained 4-MA typically also contained amphetamine and 
caffeine in varying ratios.
According to the information provided to Europol, in recent 
years multiple illicit production sites and/or other 
indications related to the production of 4-MA have been 
discovered in the Netherlands. Seizures related to 
international trafficking of 4-MA were also reported by two 
Member States, with indications of trafficking from a third 
Member State. Furthermore, Europol also reported that no 
distinct difference could be made between 4-MA and 
amphetamine in terms of the involvement of organised 
crime groups, production, trade, and/or users. No specific 
information was reported on money laundering related to 
the production and/or trafficking of 4-MA and no specific 
information was received on incidents of violence in 
prodrug of phenmetrazine) and a known norepinephrine-
dopamine releasing agent (NDRA). Phenmetrazine and 
phendimetrazine are controlled under the 1971 United 
Nations Convention on Psychotropic Substances 
(Schedule II and Schedule IV, respectively).
3.1.7. Information processing and analysis
Following the formal notification of each new substance a 
profile was created in the EDND. During 2012, 73 new 
substance profiles were created and more than 200 other 
substance profiles were updated with new information. 
These regularly updated profiles are accessed on a daily 
basis by members of the EWS network. Profiles contain a 
summary of what is known about the substance including: 
data on the nature of the substance; alerts and reports 
associated with it; information from the EMA and other 
international partners such as the United Nations; legal 
status; chemistry including molecular information, 
synthesis, manufacturing and precursor information and 
analytical data; known uses and risks associated with the 
substance; published scientific studies; reporting forms 
from Member States regarding seizures, collected samples 
and biological samples; and, any other relevant information 
that is available.
As noted in section 2.1.1, the EDND was expanded in 2012 
to include instrumental analytical data such as GC-MS, 
FT-IR and NMR spectra for the 73 new substances as well 
as additional analytical data for substances that have been 
previously notified. A total of 421 reporting forms were 
received in 2012 (26).
In addition to the reporting forms, the EMCDDA also 
implements longer-term monitoring through the collection 
of six-monthly EWS reports. Based on the information 
collected and analysed, the list of all notified substances is 
reviewed regularly by the EMCDDA and Europol in order to 
identify those with a potential to trigger a Joint report. In 
2012, two substances were considered to merit the 
production of a Joint report and are discussed below. In 
addition, a few substances are being actively and 
continually monitored due to some early indications of 
harm. Examples of these are given in section 3.3.1.
3.2. Joint reports and risk assessment
In 2012, the EMCDDA and Europol examined the available 
information on two new psychoactive substances, 4-MA 
(26)  These include notifications of the first time a new psychoactive substance is identified in a country (including the first report of a new 
substance identified in the EU) as well as significant new information on a substance (such as non-fatal intoxications, deaths, large or unusual 
seizures).
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underwent human clinical trials as an anorectic agent 
(‘Aptrol’) in the 1950s. However, its development and 
marketing was abandoned for unknown reasons and it was 
never made commercially available. It was also noted that 
the Belgian national risk assessment on 4-MA hypothesised 
that in comparison to amphetamine the more pronounced 
serotonergic action of 4-MA may diminish the stimulant 
effects of the substance leading to repeated dosing which 
may have played a role in some of the deaths (27).
The Joint report is available on the EMCDDA website (28).
3.2.2.  4-Methylamphetamine (4-MA) — Risk 
assessment
On the basis of the Joint report, on 24 September 2012, 
and in accordance with Article 6 of the Council Decision, 
the Council of the European Union requested a formal risk 
assessment of the substance.
The extended Scientific Committee of the EMCDDA 
conducted the risk assessment on 16 November 2012. The 
Committee considered the following information: the 
evidence compiled in the Joint report, updated with 
additional information where available; further detailed 
information regarding some of the deaths; case reports 
from Europol of production sites where 4-MA had been 
detected; details from the findings on the national risk 
assessments conducted by the Dutch and Belgian 
authorities; and, expert contributions from members of the 
Scientific Committee and invited experts. 
The risk assessment report is available on the Council of the 
European Union website (29). 
On 7 March 2013, after due consideration of the risk 
assessment report, the Council of the European Union 
issued a Decision to subject 4-MA to control measures 
across the EU (30). 
3.2.3. 5-(2-Aminopropyl)indole (5-IT) — Joint report
At the end of September 2012, the EMCDDA and Europol 
agreed that the information collected on 5-IT satisfied 
criteria 1, 4, 5 and 6 above (31). The two organisations 
concluded that sufficient information had been 
connection with the production, wholesale and/or 
trafficking of 4-MA.
Six Member States and Croatia reported that 4-MA was 
under drug control or equivalent legislation. Two Member 
States reported having legislation limiting the unauthorised 
supply of defined or qualifying psychoactive substances. A 
further two Member States reported that 4-MA was 
controlled under medicines legislation. It was also 
ascertained that 4-MA was not under assessment and had 
not been under assessment by the United Nations system.
The Joint report also noted that 4-methyl-benzyl methyl 
ketone (4-methyl-BMK), the precursor known to be used for 
the manufacture of 4-MA, is not under international control 
and appeared to be commercially available. 
Although some countries noted easy access and availability 
of 4-MA via the Internet, it was unclear to what extent this 
substance was advertised and sold online. There was little 
evidence to suggest a specific demand for 4-MA, however, 
as noted, the substance was reported to be sold as 
amphetamine (e.g. as ‘speed’). In this respect, the Joint 
report noted that amphetamine users may be at risk of 
exposure to 4-MA if the substance became more widely 
available, given that drug prevalence estimates suggested 
that about 2 million Europeans had used amphetamines 
during the past year.
4-MA was found to have no known medical use (human or 
veterinary) in the EU. There was no marketing authorisation 
(existing, ongoing or suspended) for 4-MA in the EU or in 
the Member States which responded to the request from 
the EMA. There were no indications that 4-MA was used for 
other purposes other than as an analytical reference 
standard and in scientific research. Further, there was no 
information to suggest that 4-MA was used in the 
manufacture of a medicinal product in the EU.
The Joint report detailed sixteen deaths and nine non-fatal 
intoxications related to 4-MA, reported by six Member States 
in a short period of time (from October 2011 to July 2012. 
The literature review that was conducted for the Joint report 
identified a limited number of studies on the chemistry, 
pharmacology and toxicology of 4-MA. Interestingly, 4-MA 
(27)  Kindly provided by the Belgian national focal point.
(28)  EMCDDA and Europol (2012), EMCDDA–Europol joint report on a new psychoactive substance, 4-methylamphetamine, EMCDDA, Lisbon. 
Available at: http://www.emcdda.europa.eu/attachements.cfm/att_191982_EN_TDAS12001ENN.PDF
(29)  Council of the European Union (2012), Risk assessment report on the new psychoactive substance 4-methylamphetamine, 17275/12 
CORDROGUE 98 SAN 320. Available at: http://register.consilium.europa.eu/pdf/en/12/st17/st17275.en12.pdf
(30)  Council Decision of 7 March 2013 on subjecting 4-methylamphetamine to control measures (2013/129/EU), OJ L 72, 15.03.2013, p. 11.
(31)   Specifically: the amount of the material seized; analogy with better-studied compounds; evidence of the potential for further (rapid) spread; 
and, evidence of cases of serious intoxication or fatalities.
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One Member State reported that 5-IT was controlled under 
drug control legislation. Two Member States controlled 5-IT 
under legislation relating to new psychoactive substances. 
One Member State controlled 5-IT under other legislation. 
One Member State controlled 5-IT under medicine 
legislation. It was also ascertained that 5-IT was not under 
assessment and had not been under assessment by the 
United Nations system.
No prevalence data were found on the use of 5-IT. In one 
case, 5-IT had been found in a ‘legal high’ type products 
called ‘Benzo Fury’. A non-representative Internet survey 
of readers of a dance music magazine found that 2.3 % of 
respondents reported use of ‘Benzo Fury’ in the last year. 
Some Member States reported easy access and 
availability of 5-IT through Internet retailers. It was noted 
that the substance was sold as a drug in its own right and 
in products branded as ‘Benzo Fury’. In the latter case, 
there was also evidence of supply from ‘bricks and mortar’ 
head shops.
The Joint report detailed 15 non-fatal intoxications and 21 
deaths associated with 5-IT in three Member States 
(Hungary, Sweden, and the United Kingdom). These were 
reported to the EMCDDA between July and December 
2012. The analysis of biological samples in some of these 
cases showed that 5-IT may have been used in conjunction 
with other new psychoactive substances and controlled 
drugs.
There appeared to be no published studies on the toxicity, 
tolerance and dependence producing potential of 5-IT. 
Detailed studies on pharmacology also did not appear to 
have been published. One available in vitro study suggested 
that 5-IT inhibited monoamine oxidase. The significance of 
this finding in relation to humans was unclear. In some of 
the non-fatal intoxications and deaths associated with 5-IT, 
symptoms typical of monoaminergic toxicity were noted.
5-IT was found to have no known human or veterinary 
medical use in the EU. There was no marketing 
authorisation (existing, ongoing or suspended) for 5-IT in 
the EU or in the Member States which responded to the 
request from the EMA. There were no indications that 5-IT 
was used for other purposes other than as an analytical 
reference material and in scientific research. At the time of 
writing the report, there was no information that 5-IT was 
used in the manufacture of a medicinal product in the EU. 
The Joint report is available on the EMCDDA website (32).
accumulated to merit the production of a Joint report on 
5-IT as stipulated by Article 5.1 of the Council Decision. In 
compliance with the provisions of the Council Decision, on 
3 October 2012 the EMCDDA and Europol launched a 
procedure for the collection of information on 5-IT, in order 
to prepare the Joint report. 
Key findings of the Joint report
5-IT is a synthetic derivative of indole, substituted at the 
phenyl side of the indole ring system (position 5). It is a 
positional isomer of alpha-methyltryptamine (AMT), which 
belongs to the chemical family of tryptamines, many of 
which are hallucinogenic. However, 5-IT also contains the 
chemical sub-structure of alpha-methylphenethylamine 
and therefore could be considered to be a substituted 
phenethylamine, many of which are known to be stimulants. 
Limited data suggest that 5-IT has stimulant effects.
The first seizure of 5-IT was in Norway on 17 April 2012, and 
was notified to the EMCDDA through the EWS on 1 June 
2012. Several EU Member States reported that forensic 
and/or toxicological laboratories did not have validated 
procedures for the confirmation of 5-IT due to the initial lack 
of certified reference material. This may have led to 
under-reporting of 5-IT. Seven Member States and Norway 
reported seizures of 5-IT, mostly as powders ranging in 
weight from 0.2 grams to 20.5 kilograms, tablets and 
capsules. It was also detected in tablets resembling 
‘ecstasy’ in one Member State.
The information available for the Joint report suggested that 
common routes of administration of 5-IT were orally and by 
insufflation. One Member State reported that injection of 
the substance may also be occurring.
There was no information regarding manufacturing sites, 
the chemical precursors or the synthetic routes used for the 
5-IT that had been detected on the drug market. One 
possible route of synthesis was a similar process to the 
reductive amination used commonly in the manufacture of 
amphetamines. The reactions were thought to be feasible in 
an amateur laboratory setting and not to require 
sophisticated equipment.
According to reports provided to Europol there was no 
information available to suggest the involvement of 
organised crime, nor criminal groups, in the production, 
distribution and trafficking of 5-IT. The substance had been 
seized at the border of four Member States and Norway. In 
one case this involved a seizure of 20.5 kilograms of powder.
(32)  EMCDDA and Europol (2012), EMCDDA–Europol joint report on a new psychoactive substance, 5-(2-aminopropyl)indole, EMCDDA, Lisbon. 
Available at: http://www.emcdda.europa.eu/publications/joint-reports/5-IT
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Methylone
In January 2012, an alert was issued after the publication of 
case report that described the details of a death associated 
with the synthetic cathinone derivative methylone 
(3,4-methylenedioxymethcathinone). The death involved a 
16-year-old male, and was the first involving methylone to 
be brought to the attention of the EMCDDA. 
Methylone was first notified in 2005 and was one of the first 
synthetic cathinones to be monitored by the EWS.
Methoxetamine
Methoxetamine is an arylcyclohexylamine and is chemically 
related to ketamine. The substance was first notified at the 
end of 2010. An alert was issued in 2011 after publication 
of a case series of non-fatal intoxications by researchers in 
the United Kingdom. In 2012, two more alerts were issued 
in relation to methoxetamine.
The first alert of 2012 was issued in February after the 
Italian national focal point reported a non-fatal intoxication 
associated with methoxetamine that involved a 27-year-old 
male. The report stated that the patient was tachycardic, 
confused, hallucinating and severely agitated.
The second alert was issued in June after the Swedish 
national focal point notified the EMCDDA of a death in 
which methoxetamine, synthetic cannabinoids and THC 
were detected in post-mortem samples.
Also in 2012, upon request from the United Kingdom 
national focal point, the EMCDDA launched an informal 
information request on this substance. The responses were 
used by the Advisory Council for the Misuse of Drugs in 
their advice to the government that methoxetamine should 
be controlled under drugs legislation. The legislation placing 
methoxetamine into the United Kingdom’s drug control law 
was passed on 26 February 2013.
Alpha-methyltryptamine
Alpha-methyltryptamine (AMT), a substituted tryptamine, 
was first notified by Finland in 2001 under the 1997 Joint 
Action (35). It was developed in the Soviet Union as an 
anti-depressant in the 1960s. Over the past few years, it 
has been widely offered by Internet retailers selling new 
psychoactive substances.
On the basis of the information provided in the Joint report, 
on the 24 January 2013, the Council of the European Union 
requested that a formal risk assessment be conducted on 
the substance. The risk assessment will be conducted by 
the extended Scientific Committee of the EMCDDA in April 
2013.
3.3. Public health alerts
Providing warnings on the adverse health effects of new 
psychoactive substances through timely and rapid public 
health alerts is one of the activities of the EWS that 
provides added value to the Member States (33). In addition, 
the EWS stimulates the exchange of information on 
emerging trends in new uses of existing psychoactive 
substances that may pose a potential risk to public health, 
as well as information on possible public health related 
measures, in accordance with the mandate and procedures 
of the EMCDDA.
In 2012, the EWS issued public health alerts to the network 
concerning noteworthy or unusual hazards related to new 
psychoactive substances and controlled drugs (34).
3.3.1. Alerts related to new psychoactive substances
In 2012, the EMCDDA issued public health alerts 
concerning adverse health effects related to seven new 
psychoactive substances and one ‘legal high’ product.
5-(2-Aminopropyl)indole (5-IT)
Three public health alerts were issued in relation to the 
substituted indole 5-IT. These alerts were issued in July, 
September and October 2012 and were triggered by 
reports of non-fatal intoxications and/or deaths from the 
Swedish, Hungarian and the United Kingdom national focal 
points. This information also played a key role in the 
decision by the EMCDDA and Europol to launch a Joint 
report on the substance (section 3.2.3). Since the 
submission of the Joint report to the Council of the 
European Union, the European Commission and the EMA in 
December 2012, a further three deaths (two in Hungary 
and one in Germany) have been reported to the EMCDDA 
through the EWS. 
As noted in section 3.2.3, a formal risk assessment on 5-IT 
will be conducted on 11 April 2013.
(33) Such alerts are not legally binding and therefore Member States are not obliged to act upon them.
(34) Note that detection of new psychoactive drugs in post-mortem samples does not necessarily imply a causal role in the death.
(35)  Joint Action 97/396/JHA of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty on European Union, concerning the 
information exchange, risk assessment and the control of new synthetic drugs. OJ L 167, 25.06.1997, p. 1. 
21
Formal activities
to the state laboratory, the urines of the decedents 
contained PMMA, MDMA, an anti-histamine and codeine.
4-Methylamphetamine (4-MA)
Three public health alerts were issued in 2012 in relation to 
4-MA, which was the subject of a Joint report and risk 
assessment (sections 3.2.1 and 3.2.2). These alerts related 
to reports of deaths in the Netherlands, Belgium and the 
United Kingdom, and followed the initial alert issued in 
October 2011 after the Belgian national focal point reported 
three non-fatal intoxications and three deaths associated 
with the substance. 
Methylthienylpropamine
Methylthienylpropamine (MPA) is the thiophene analogue 
of N-methylamphetamine. It was first notified in January 
2011 by Finland. Two separate alerts were issued in 2012 
when the United Kingdom national focal point reported 
three cases involving deaths associated with this 
substance.
The first alert concerned two cases. The first case involved 
a ‘legal high’ product known as ‘Blow’ that was suspected 
to have been snorted. Analysis of the product contents 
found MPA, MDAI (methylenedioxyaminoindane), 
lignocaine, and caffeine. These drugs were also detected in 
the post-mortem samples but mainly MPA. In the second 
case, MPA and methoxetamine were detected. The 
information from this case suggested that a ‘legal high’ 
product called ‘China White’ had been snorted by the 
deceased. The deceased had no other significant 
toxicological findings.
The second alert related to a case where MPA was detected 
in post-mortem blood along with oxycodone, temazepam, 
venlafaxine and its metabolite o-desmethylvenlafaxine. No 
other illicit drugs or new psychoactive substances were 
found.
‘Annihilation’
A public health alert was issued on ‘Annihilation’, which is 
a ‘legal high’ product rather than a specific substance. In 
October 2012, as a result of media reports, the EMCDDA 
contacted the United Kingdom national focal point 
regarding a product called ‘Annihilation’, which was 
Two alerts regarding AMT were issued in 2012 after 
information was received regarding deaths in the United 
Kingdom and Norway.
The first of the alerts was issued after the United Kingdom 
national focal point reported two deaths that occurred in 
2011. In one case, AMT was found in two different post-
mortem samples. In the other case, MDMA, 
fluoromethcathinone, AMT, methylone, MDPV, MDAI, 
methoxetamine and 5-IAI were detected post-mortem. It 
was reported that this case appeared to involve the use of 
separate products rather than one product containing all 
these substances. 
The second public health alert was issued after the 
Norwegian national focal point reported the death of a 
19-year-old male whose post-mortem toxicological analysis 
revealed high concentrations of AMT in the blood. Alcohol 
and other drugs were not detected.
Para-methyoxyamphetamine (PMA) and para-
methoxymethamphetamine (PMMA)
PMA and PMMA are substituted phenethylamine 
substances which have been associated with serious 
toxicity including death. PMMA was risk-assessed in 2001 
in the framework of the 1997 Joint Action (36) and 
consequently subject to control measures across the 
EU (37).
Alerts were issued on PMMA/PMA in both 2010 and 2011. 
In 2012, two public heath warnings were issued after 
serious non-fatal intoxications and deaths were reported 
from the United Kingdom and Ireland.
The United Kingdom national focal point provided a report 
of four serious non-fatal intoxications and one death that 
were believed to be associated with the use of tablets that 
contained PMA. In a second case, there were a further two 
fatalities where PMA was detected post-mortem. Further 
details were not available at the time of the alert. Also at 
that time, the United Kingdom national focal point reported 
three further deaths associated with PMA from 2011 that 
had not been previously reported to the EMCDDA. 
A further alert on PMA/PMMA was issued when the Irish 
national focal point reported two deaths associated with 
the use of a drug containing PMMA and MDMA. According 
(36)  EMCDDA (2003), Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs, Office for Official 
Publications of the European Communities, Luxembourg.
(37)  Council Decision of 28 February 2002 concerning control measures and criminal sanctions in respect of the new synthetic drug PMMA 
(2002/188/JHA). OJ L 63, 06.03.2002, p. 14.
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Fentanyl
An alert was issued in March 2012 on the request of the 
German national focal point due to an observed marked 
increase in deaths associated with the use of fentanyl. In 
2011, 24 % of all drug-related deaths recorded in the 
Bavaria region were associated with fentanyl use.
A further alert on fentanyl was issued following a media 
report that highlighted the issue of fentanyl misuse in 
Estonia.
A Trendspotter meeting was held in Lisbon in October 2012 
to examine the use of fentanyl and fentanyl derivatives in 
Europe (section 4.2).
Anthrax infection associated with heroin use
Several alerts were issued during the course of 2012 
regarding outbreaks of anthrax infection in users who 
injected heroin. The United Kingdom, German, French and 
Danish national focal points reported confirmed cases of 
anthrax between the 13 June 2012 and 19 December 
2012. There were six cases in the United Kingdom, four in 
Germany, one in France and one in Denmark. During this 
period, the EMCDDA worked closely with the relevant 
authorities in the Member States and with the European 
Centre for Disease Control (ECDC). A Joint ECDC–
EMCDDA rapid risk assessment was conducted in June 
with relevant advice and public health warnings issued on a 
rolling basis as updates were received (39).
reported to be responsible for a series of non-fatal 
intoxications in Scotland, United Kingdom. The national 
focal point reported that analyses of five samples of 
‘Annihilation’ revealed the presence of mixtures of 
synthetic cannabinoids, and that the contents of different 
packages of the product were not the same. Furthermore, 
a search of the EDND revealed that the German national 
focal point had previously reported a seized sample of 
‘Annihilation’. The results of these analyses are presented 
below. 
Of note is that all the samples contained the synthetic 
cannabinoid UR-144 (first notified to the EMCDDA in 
February 2012 by the Finnish national focal point). However, 
it is not known whether this substance caused the effects 
that were reported to be associated with the consumption 
of this product. UR-144 is a synthetic cannabinoid that was 
developed as a selective CB2 receptor ligand with lower 
affinity for the CB1 receptor (the main endogenous 
cannabinoid receptor responsible for psychoactive 
effects) (38).
Europol also issued an alert to the network of Europol 
National Units regarding ‘Annihilation’ products.
3.3.2. Alerts related to controlled substances
In 2012, public health alerts were also issued in relation to 
three internationally controlled substances. These were 
fentanyl, heroin and methamphetamine 
(N-methylamphetamine).
Table 1. Synthetic cannabinoids found in ‘Annihilation’ ‘legal high’ products, October 2012
Source of data UR-144 MAM-2201 AM-2201
JWH-122
pentenyl derivative
AM-1248
UK ü ü — ü —
UK ü ü — — —
UK ü ü ü ü —
UK ü — ü — —
UK ü ü — — —
Germany ü ü — — ü
(38)  Poso, A. and Huffman, J. W., (2008), Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands, 
British Journal of Pharmacology, 153(2), pp. 335–346.
(39)  ECDC and EMCDDA (2012), Joint ECDC and EMCDDA rapid risk assessment. Anthrax cases among injecting drug users, Germany, ECDC, 
Stockholm.
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3.3.3. Emerging trend for future monitoring
The EMCDDA has noted that some of the most potent new 
psychoactive substances, such as the phenethylamines 
substituted with the ‘-NBOMe’ group (section 3.1.2) and 
fentanyls, are being offered for sale online as cyclodextrin 
complexes. 
Cyclodextrin complexes are large synthetic molecules 
produced from starch. They have many legitimate 
applications including as potential drug delivery methods. 
This is because they form so-called ‘host-guest complexes’, 
where a drug molecule can be chemically bound to the 
cyclodextrin but then released on ingestion. Such a 
mechanism of action could have benefits for producers, 
distributors and users of particularly potent new 
psychoactive substances as it would render them easier 
and safer to handle. On the other hand, the use of 
cyclodextrin complexes as a vehicle to carry drugs may 
have implications for the identification of new substances 
using established detection techniques. Furthermore, it is 
possible that this mode of delivery may also increase the 
capacity for further spread of these ‘difficult to handle’ 
drugs.
Methamphetamine (N-methylamphetamine)
Three public health warnings were issued in relation to 
methamphetamine in 2012.
In early 2012, an alert was issued in response to a report 
from the Greek national focal point concerning the death of 
a drug user, thought to be from the use of 
methamphetamine. This substance has emerged onto the 
drug scene in Greece and is known locally as ‘sisa’. Two 
seizures of ‘sisa’ by police in central Athens were found to 
contain methamphetamine in crystalline form (commonly 
called ‘crystal meth’). 
A further alert was issued later in the year after an update 
by the Greek national focal point that concerned further 
seizures of ‘sisa’ along with reports of drug users 
approaching treatment services seeking help in relation to 
the substance. 
The third alert was triggered by the report of a second death 
in Greece, which involved a female drug user. In this case, 
methamphetamine, methadone and morphine were 
confirmed in the post-mortem blood samples.
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the last month), and lifetime use of mephedrone was 0.4 % 
(0.3 % in the last year and 0.2 % in the last month) (41). 
The 2010/11 British Crime Survey (42) found that among the 
general population (16–59) in England and Wales, last year 
use of mephedrone (1.4 %) was at a level similar to that of 
ecstasy. Among the 16–24 age group, last year prevalence 
of mephedrone was the same as that of powder cocaine 
(4.4 %). Most of those who reported using mephedrone in 
the last year also reported having used another illicit drug 
(mainly cannabis, cocaine or ecstasy). An important caveat 
to understanding the significance of these results is that 
the data collection for the survey covered some time before 
and after the period when mephedrone was controlled. The 
2011/12 survey (43, 44) found that last year use of 
mephedrone among adults aged 16 to 59 was 1.1 %. 
Mephedrone was found to be the fourth most prevalent 
drug measured. Among 16- to 24-year-olds, last year use 
was 3.3 %, the same level as ecstasy, the third most 
prevalent drug used within this age group. Estimates of use 
of recently controlled drugs (GBL/GHB, BZP and synthetic 
cannabinoids) in the last year ranged between 0.1 and 
0.2 % for each type of drug.
Mephedrone and ‘legal highs’ were included for the first 
time in a joint household survey in Ireland and Northern 
Ireland (United Kingdom) conducted in 2010/11, after 
mephedrone was controlled (45). The sample included over 
7 500 respondents, aged 15–64. In Northern Ireland, 
lifetime prevalence was estimated at 2 % and last year 
prevalence at 1 % for both mephedrone and ‘legal highs’. 
Lifetime prevalence levels were higher among those aged 
15–24, reaching 6 % for both mephedrone and ‘legal highs. 
4.1.  Overview of prevalence data on new 
psychoactive substances 
Data on both the prevalence of use and associated user 
behaviours are essential components to monitoring, 
understanding, and, responding to, the phenomenon of new 
psychoactive substances. Such data are currently limited 
and may suffer from methodological limitations, including a 
lack of common definitions. In addition, most users do not 
know which substances they have actually taken. This may 
be a particular problem regarding ‘legal high’ products 
(such as smoking mixtures that contain synthetic 
cannabinoids) that are sold using brand names as normally 
no information is provided about the contents, and, in any 
case, the contents of a particular product may vary over 
time. Finally, data are reported with a time delay, which 
needs to be taken into account considering the highly 
dynamic and fast-moving market in new psychoactive 
substances.
Over the past few years some representative general 
population surveys have been conducted that examine the 
prevalence of ‘legal highs’ and new psychoactive 
substances in school students and/or adults (40).
A national survey of Spanish students (aged 14–18) 
conducted in 2010 found overall lifetime use of ‘legal highs’ 
of 0.7 % (0.6 % in the last year and 0.5 % in the last month). 
While the lifetime use of ‘research chemicals’ was 0.4 % 
(0.3 % in the last year, and 0.2 % in the last month), lifetime 
use of ‘Spice’ products (which contain synthetic 
cannabinoids) was 1.1 % (0.8 % in the last year and 0.4 % in 
4. Epidemiology and new approaches
(40)  For some new drugs that are sold directly on the illicit market, the user groups and prevalence may, to some degree, reflect those for 
established controlled drugs (such as amphetamine and MDMA). A recent example of this was 4-methylamphetamine, which was usually sold 
as amphetamine (e.g. ‘speed’), even though users were mostly unaware of this.
(41)  Clinical Committee of the Government Delegation for the National Plan on Drugs (2011), Emerging drugs. Report 6 of the Clinical Committee, 
Ministry of Health, Madrid. Available at: http://www.pnsd.msc.es/Categoria2/publica/pdf/DROGAS_EMERGENTES_ingles_WEB.pdf
(42)  Smith, K. and Flatley, J (2011), Drug Misuse Declared: Findings from the 2010/11 British Crime Survey, Home Office, London.
(43)  In 2012, the British Crime Survey was renamed the Crime Survey of England and Wales.
(44)  UK Home Office (2012), Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales, Home Office, London.
(45)  National Advisory Committee on Drugs (NACD) and Public Health Information and Research Branch (PHIRB) (2011), Drug use in Ireland and 
Northern Ireland: first results from the 2010/11 Drug Prevalence Survey. Bulletin 1. NACD & PHIRB, Dublin.
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nightlife settings in the Czech Republic found that 4.5 % of 
a sample of 1 091 Internet users aged 15 to 34 reported 
use of a new psychoactive substance (48). 
In 2011, the online drug-use survey for the UK clubbing 
magazine Mixmag and the Guardian newspaper (49) which 
draws on previous Mixmag surveys collected 15 500 
responses from around the world, but mostly from the 
United Kingdom. In 2010/11, reported levels of use of 
mephedrone in the last year and last month were three 
times higher among clubbers (30 % and 13 %) than 
non-clubbers (10 % and 3 %).
4.2. Trendspotter study: fentanyl in Europe
The second EMCDDA Trendspotter study was conducted in 
October 2012 and examined the availability and use of 
fentanyl in Europe, including: the extent and patterns of use; 
illicit production and diversion; harms and deaths; and, 
responses to the problem. Twelve experts from 10 Member 
States (Bulgaria, Czech Republic, Germany, Estonia, 
Greece, Italy, Slovakia, Sweden, Finland, United Kingdom) 
attended the meeting, presenting their experiences and 
contributing to an analysis of the topic, providing insights 
from law enforcement, forensic science, treatment, 
research and monitoring, and drug user perspectives.
The EMCDDA Trendspotter study methodology 
incorporates a number of different investigative 
approaches and data collection from multiple sources. This 
study included: a review of the international literature; data 
collection from the 30 national early warning systems; data 
collection on fentanyl-associated deaths; 12 expert 
presentations (from 10 countries); an electronic survey of 
experts attending the meeting; and, three facilitated 
working groups. Analysis was based on triangulation of the 
available data, with a view to providing as complete and 
reliable a picture as possible, with an important caveat 
being that much of the data are preliminary and many of 
the results are based on expert opinion and the grey 
literature.
The report from the meeting is available on the EMCDDA 
website (50).
In Ireland, new psychoactive substances (last year use, 4 %) 
were the second most frequently reported illicit drugs after 
cannabis (6 %). The highest levels of last year use of new 
psychoactive substances were reported by 15- to 24-year-
olds (10 %).
In addition, a 2011 Eurobarometer survey of youth attitudes 
to drugs, which interviewed more than 12 000 young 
people aged between 15 and 24, estimated that 5 % of 
young Europeans had used ‘legal highs’ at some time, with 
about half of the countries falling in the range 3–5 %. The 
highest estimates were reported by Ireland (16 %) followed 
by Latvia, Poland and the United Kingdom (all at nearly 
10 %) (46).
Surveys have also examined the use, availability and 
associated user behaviours in targeted populations such as 
nightclub patrons and dance music fans. The targeted 
populations tend to include ‘early adopters’ of new drugs. 
The findings of these surveys are not generalisable to other 
groups and populations. Nevertheless, the use of new drugs 
in these targeted populations can be very high and such 
studies may provide insights into the harms a drug may 
have, as well as an indication of substances that may be 
attractive to other user groups and which could become 
more widespread. 
A survey of individuals attending ‘gay friendly’ nightclubs in 
south-east London in 2011 found that, among 313 
participants, lifetime use of a ‘legal high’ was reported by 
65.8 %. Lifetime use of mephedrone was reported by 
63.8 % of the sample (last month use was 53.2 % and use 
during the day of the survey was 41 %). In addition, lifetime 
use of BZP was 9.3 % (1.6 % in the last year); lifetime use of 
MDAI was 7.7 % (1.3 % in the last year); lifetime use of 
‘synthetic cocaine’ was 9.9 % (3.5 % in the last year); 
lifetime use of ‘Spice/K2’ was 9.9 % (2.2 % in the last year); 
lifetime use of methoxetamine was 6.4 % (1.9 % in the last 
year); and lifetime use of ‘pipradrols’ was 1.6 % (1.0 % in the 
last year) (47).
An online survey on ‘legal highs’ conducted among 860 
respondents with experience in ‘legal highs’ in Germany 
showed that ‘herbal blends’ were the most prevalent ‘legal 
high’ products, followed by ‘research chemicals’ and ‘bath 
salts’ and similar products. Similarly, a study carried out in 
(46)  Gallup Organization (2011), Youth attitudes on drugs, Flash Eurobarometer 330. Available at: http://ec.europa.eu/public_opinion/flash/
fl_330_en.pdf
(47)  Wood, D. M., Hunter, L., Measham, F. and Dargan, P.I. (2012), ‘Limited use of novel psychoactive substances in South London nightclubs’, 
Quarterly Journal of Medicine, 105(10), pp. 959–64.
(48)  EMCDDA (2012), Annual report 2012: the state of the drug problem in Europe, Publications Office of the European Union, Luxembourg, p. 92.
(49) No authors listed (2012), ‘Global drug survey’, Mixmag, 251, pp. 68–73.
(50) http://www.emcdda.europa.eu/scientific-studies/2012/trendspotters-report
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to assist with the monitoring and risk assessment of new 
psychoactive substances.
This technique is based on the fact that molecules with 
similar chemical structures may possess similar 
physicochemical properties and biological activities. The 
concept of molecular similarity has been exploited in drug 
discovery, and similarity methods have been used in the 
prediction of physicochemical properties (solubility, 
partitioning coefficient), as well as estimating absorption, 
distribution, metabolism, excretion and toxicity. 
This method may be useful, both at an early stage in the 
process of assessing new psychoactive substances and as 
a complementary technique during the risk assessment. 
However, it is not a tool that can be used on its own in the 
risk assessment process. 
Using the computational modelling method, 4-MA was 
examined and was predicted to have properties similar to 
other substituted amphetamine stimulants. Other 
compounds assessed using this technique in 2012 were 
5-IT, alpha-PVP and methoxetamine.
5-(2-Aminopropyl)indole (5-IT)
The computational modelling method predicted that the 
5-HT
2C
 and 5-HT
1D
 receptors were possible targets of 5-IT. 
These receptors are known to be involved in the reward 
circuit of the limbic part of the brain. In addition, the model 
predicted that 5-IT may cross the blood–brain barrier. 
Alpha-PVP
Alpha-PVP belongs to the group of pyrrolidinophenone type 
drugs, structurally similar to pyrovalerone (4-methyl-α-
pyrrolidinovalerophenone) which acts by releasing 
dopamine and norepinephrine. It was predicted that this 
compound would affect the dopaminergic and 
norepinephrinergic systems, in agreement with data from in 
vitro studies. In addition, the model predicted that alpha-
PVP may be able to cross the blood–brain barrier.
Methoxetamine
The target prediction algorithm was not able to predict the 
expected targets for ketamine and methoxetamine. The 
limitations of the technique at the present time for certain 
groups of compounds must be acknowledged.
This meeting built upon the success of the first EMCDDA 
Trendspotter meeting which took place in Lisbon in October 
2011, and examined the recent shocks in the European 
heroin market (51).
4.3. Sewage epidemiology
Sewage epidemiology, also known as wastewater analysis, 
is a rapidly developing scientific discipline. It has been 
supported by the EMCDDA as it was recognised that this 
may be a useful epidemiological technique to help support 
the Agency’s work. Monitoring population-level trends in 
illicit and new drug consumption using this technique is 
now feasible given the recent advances in analytical 
chemistry and applied research that allow the 
identification of illicit and new drugs as well as their main 
metabolites in wastewater at very low concentrations. This 
is comparable to taking a much diluted urine sample from 
an entire community (rather than from an individual user). 
With certain assumptions, it may be possible to back-
calculate from the amount of the metabolite in the 
wastewater to an estimate of the amount of a drug 
consumed in a community. Early research focused on 
identifying cocaine and its metabolites in wastewater, but 
recent studies have shown that this technique shows 
promise for monitoring consumption of new psychoactive 
substances.
Two expert meetings on wastewater analysis were 
organised by the EMCDDA in 2011. These were followed up 
with a demonstration project commissioned by the 
EMCDDA (2012) that aimed to explore the applicability of 
the technique through the analysis of wastewater in 19 
European cities. In December 2012, the EMCDDA hosted a 
workshop that examined how illicit drug use in populations 
could be determined through wastewater biomarker 
analysis. The workshop brought together some of the 
leading researchers in this field and was an effective 
platform for the kick-off meeting of the SEWPROF (sewage 
profiling) project group (52). 
4.4.  Computer-aided prediction of 
pharmacological properties 
The EMCDDA–Europol 2011 Annual Report on the 
implementation of Council Decision 2005/387/JHA 
discussed the potential of using computer-based modelling 
(51) http://www.emcdda.europa.eu/scientific-studies/2011/trendspotters-report
(52)  SEWPROF is a research project funded by the European Commission, Marie Curie Actions, Seventh Framework Programme and the Initial 
Training Network to develop interdisciplinary and cross-sectoral research capability for the next generation of scientists working in the 
newly-emerging field of sewage epidemiology. 
27
substance sought, and in some cases may actually contain 
controlled drugs.
The new psychoactive substances seized by European law 
enforcement agencies are sourced mainly from China and 
to a lesser extent from India. The illicit production of new 
drugs inside the EU is rarely reported to Europol by Member 
States. This may perhaps be due to the requirement for 
more sophisticated methods of synthesis and equipment 
required, when compared to the ‘traditional’ synthetic drugs 
such as amphetamine and MDMA. In the majority of cases 
reported by Member States, ‘illicit production’ of new 
psychoactive substances in the EU has referred to 
professional mixing and packaging sites, rather than 
synthesis of the substances.
During the preparation for the EMCDDA–Europol Joint 
report on 4-MA, an interesting finding was noted regarding 
the precursors for new drugs. The Netherlands reported 
that in recent years multiple illicit production sites and/or 
incidents related to the production of 4-MA had been 
discovered (three sites in 2010 and one site in 2011). In 
each case it was not clear whether the criminals involved in 
the illicit production were aware that they were producing 
4-MA. According to Dutch intelligence, there were 
suggestions that some producers believed that they were 
producing amphetamine using the precursor BMK, when 
they were actually using the precursor 4-methyl-BMK and 
consequently producing 4-MA.
5.1. Europol 
As a key partner in the system set up under the Council 
Decision, Europol is at the forefront of monitoring, 
knowledge sharing and awareness of the regional supply of 
new psychoactive substances. The role that Europol plays 
under the Council Decision allows it to have a regional 
overview and develop expertise concerning the production, 
trafficking and organised crime involvement in both the 
‘traditional’ synthetic drugs market as well as on new 
psychoactive substances. Europol has several expert 
systems which incorporate synthetic drug related data, 
including new psychoactive substances. 
The extensive involvement of organised crime in the 
production, trafficking and marketing of synthetic drugs is 
well-known. Further to this, information gathered by Europol 
shows that organised crime continues to exploit new 
market opportunities, with production or packaging, mixing 
and trafficking of new drugs posing an emerging threat to 
the EU.
Moreover, the Internet has become a major new 
marketplace for such new psychoactive substances as well 
as an information hub for sharing knowledge on their 
synthesis, effects and availability. However, Europol has 
noted that new psychoactive substances advertised on the 
Internet as ‘legal highs’ are not always consistent with the 
5. Production and distribution of new psychoactive substances
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Now, more than ever, the EWS provides added value to the 
Member States by playing an essential role in ensuring that 
they have access to the most up-to-date information on 
new psychoactive substances both from across Europe and 
beyond. The EWS network continues to grow, as does the 
amount and quality of the information that it collects. The 
network now includes not only new forensic science and 
toxicological laboratories, but also a range of health and law 
enforcement professionals, as well as many academic 
researchers. It is clear that the EWS functions efficiently 
and effectively due to the structure that is underpinned by 
the Reitox national focal points, the technical expertise that 
has been built up by members of the network, the clear 
operating guidelines and the coordination provided by the 
EMCDDA and Europol. 
Further, where necessary, the system allows for the 
progression through the scientific risk assessment phase to 
control measures across the EU. In 2012, this sensitive 
monitoring system provided the EMCDDA and Europol with 
the signals required to trigger Joint reports for 4-MA and 
5-IT. After the risk assessment conducted by the extended 
Scientific Committee of the EMCDDA, and following 
opinion of the European Commission, the Council of the 
European Union decided to control 4-MA across the Union. 
The risk assessment of 5-IT will be conducted in April 2013. 
Sound scientific data are essential to the system set up by 
the Council Decision. In order to better inform the 
responses that are likely to be needed to address the new 
drugs phenomenon, there are some key areas of the EWS 
that need to be strengthened. These include:
•  the data collection and data management infrastructure 
of the EWS, including the EDND (which was not designed 
to handle the quantity and range of data that is now 
generated by the new drugs phenomenon); 
•  provision of a mechanism to produce and share analytical 
reference standards across the EU;
•  improving the capacity for investigative analysis and 
applied research at the European level; and,
•  epidemiological studies, particularly targeted and general 
population prevalence surveys. 
Until about a decade ago, most new psychoactive 
substances were typically sold directly on the illicit market. 
They were produced in illicit production facilities and called 
‘designer drugs’ or were sourced from diverted medicines. 
To some degree, this continues to be the case, with 4-MA 
being the latest example of a new drug produced in illicit 
production facilities within the EU. However, the emergence 
of ‘legal highs’, beginning with BZP and methylone, and 
followed by mephedrone, marked a fundamental shift in the 
drug markets. Now many new psychoactive substances are 
produced in bulk in China and India and imported into 
Europe, where they are processed, packaged and sold on 
the growing ‘legal highs’ market. These developments have 
been fuelled by globalisation and technological 
advancement, which have also allowed a more open market 
to develop. This includes advertisement and sale through 
the Internet and ‘bricks and mortar’ head shops. In addition, 
for suppliers, the Internet is also facilitating communication 
as well as providing access to knowledge, expertise and 
logistics. For users, the Internet has made it easier to learn 
about ‘legal highs’, share their experiences of using them 
and provide advice and support to other users. Overall, 
these developments have played a role in the 
dramatic increase in the number, type and availability of 
new psychoactive substances in Europe. In 2012, 73 new 
substances were officially notified for the first time in 
Europe through the EWS, with more than 280 substances 
now being monitored by the EMCDDA. 
The globalised nature of the new drugs phenomenon makes 
it particularly difficult to control and reduce supply. 
Differences in drug laws between EU Member States and 
third countries, such as China and India, where the 
substances are manufactured, compound the problem. 
Retailers exploit gaps in existing control and regulatory 
measures and rapidly adapt to new measures. Insufficient 
capacity for screening freight and postal packages makes it 
difficult to prevent new drugs entering the EU. The 
decentralised and transnational nature of the Internet 
means that enforcement measures may have a limited 
impact due to displacement of online shops to countries 
outside the EU, where legal and regulatory systems may be 
inadequate to address this phenomenon. 
6. Conclusions
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psychoactive substances (such as receptor binding and 
mode of action studies) that will help provide the evaluation 
of potential acute and chronic toxicity in humans. While the 
EMCDDA has applied such techniques on an ad hoc basis 
in the past, it is clear that such information will be required 
on a routine, systematic basis in the future.
Conclusions
Finally, advances in the fields of pharmacology and 
toxicology now allow for the more rapid assessment of the 
properties of new substances. These data can be used to 
improve the knowledge and understanding of these 
substances, including, critically, for the risk assessment 
process. Such an assessment may include the study of the 
pharmacological and toxicological properties of new 
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14.  URB754 (6-methyl-2-[(4-methylphenyl)amino]-1-
benzoxazin-4-one) – 27 February 2012 – Bulgaria 
15.  5-APDB (5-(2-aminopropyl)-2,3-dihydrobenzofuran) 
– 5 March 2012 – Bulgaria 
16.  Phenibut (4-amino-3-phenyl-butyric acid) – 8 March 
2012 – Sweden 
17.  6-APDB (6-(2-aminopropyl)-2,3-dihydrobenzofuran) 
– 8 March 2012 – Spain 
18.  2-FMA (2-fluoro-N-methyl-amphetamine) – 12 March 
2012 – Finland
19.  ECX (1-ethynyl-1-cyclohexanol) – 26 March 2012 
– United Kingdom
20.  4-Fluoroephedrine (1-(4-fluorophenyl)-2-(methylamino)
propan-1-ol) – 26 March 2012 – United Kingdom
21.  3-MeO-PCP (1-[1-(3-methoxyphenyl)cyclohexyl]
piperidine) – 29 March 2012 – United Kingdom
22.  5FUR-144 ((1-(5-fluoropentyl)-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)methanone) – 30 
March 2012 – Latvia 
23.  25D-NBOMe (2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
methoxybenzyl)ethanamine) – 16 April 2012 – United 
Kingdom
24.  A-796,260 ([1- [2- (4- morpholinyl)ethyl]- 1H- indol- 3- yl](2, 
2, 3, 3- tetramethylcyclopropyl)methanone) – 18 April 
2012 – Belgium 
25.  4-AcO-DALT (4-acetoxy-N,N-diallyltryptamine) – 20 
April 2012 – Finland 
26.  1-Phenyl-2-(piperidin-1-yl)butan-1-one – 7 May 2012 
– Spain
1.  HU-331 ((3S,4R)-3-hydroxy-2-p-mentha-(1,8)-dien-3-
yl-5-pentyl-3,4-p-benzoquinone) – 12 January 2012 – 
France
2.  AM-679 ((2-iodophenyl)(1-pentyl-1H-indol-3-yl)
methanone) – 27 January 2012 – Italy
3.  WIN 55212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-
yl]-1-napthalenylmethanone) – 27 January 2012 – Italy
4.  UR-144 ((1-pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethyl-
cyclopropyl)methanone) – 1 February 2012 – Finland 
and Poland 
5.  JWH-370 ([5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-
yl]-1-naphthalenyl-methanone) – 1 February 2012 – 
Finland
6.  N-propylamphetamine (N-(1-phenylpropan-2-yl)
propan-1-amine) – 3 February 2012 – Austria
7.  3-(p-Methoxybenzoyl)-N-methylindole – 3 February 
2012 – Austria
8.  trans-Diastereomer of CP 47,497-C8 homologue – 3 
February 2012 – Austria
9.  1-Cyclohexyl-x-methoxybenzene – 3 February 2012 
– Austria
10.  3-Fluoro-isomethcathinone (1-(3-fluorophenyl)-1-
(methylamino)-2-propanone) – 13 February 2012 – 
Czech Republic
11.  1-(3-Methylbenzyl)piperazine – 17 February 2012 
– Sweden 
12.  2-Fluoroamphetamine (1-(2-fluorophenyl)propan-2-
amine) – 21 February 2012 – Sweden 
13.  Thienoamphetamine (1-(thiophen-2-yl)propan-2-amine) 
– 24 February 2012 – Czech Republic
Annexes
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43.  AM-694 methyl substituted for iodine 
(1-(5-fluoropentyl)-3-(2-methylbenzoyl)indole) – 18 
July 2012 – United Kingdom
44.  AM-694 ethyl substituted for iodine 
(1-(5-fluoropentyl)-3-(2-ethylbenzoyl)indole) – 18 July 
2012 – United Kingdom
45.  JWH-018 N-(5-chloropentyl) derivative 
([1-(5-chloropentyl)-1H-indol-3-yl](naphthalen-1-yl)
methanone) – 31 July 2012 – Germany
46.  JWH-018 N-(5-bromopentyl) derivative 
([1-(5-bromopentyl)-1H-indol-3-yl](naphthalen-1-yl)
methanone) – 31 July 2012 – Germany
47.  AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)
cyclohexyl]methyl]benzamide) – 2 August 2012 – 
United Kingdom 
48.  4-AcO-DPT (4-acetoxy-N,N-dipropyltryptamine) – 21 
August 2012 – Finland 
49.  Pyrazolam (8-bromo-1-methyl-6-phenyl-4H- [1,2,4]
triazolo[4,3a][1,4]benzodiazepine) – 22 August 2012 
– Finland
50.  2-MeO-Ketamine (2-(2-methoxyphenyl)-2-
(methylamino)cyclohexanone) – 30 August 2012 – 
Sweden
51.  Hydroxyamphetamine (4-(2-aminopropyl)phenol) – 5 
September 2012 – Poland
52.  3-Methylmethcathinone / 3-MMC (1-(3-methylphenyl)-
2-(methylamino)propan-1-one) – 5 September 2012 
– Sweden
53.  N-Ethylnorketamine (2-(2-chlorophenyl)-2-(ethylamino)
cyclohexanone) – 17 September 2012 – United 
Kingdom
54.  5-APDI (1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine) 
– 17 September 2012 – United Kingdom
55.  AM-1248 (1-[(N-methylpiperidin-2-yl)methyl]-3-
(adamant-1-oyl)indole) – 24 September 2012 – 
Germany
56.  AKB-48F (N-(1-adamantyl)-1-(5-fluoropentyl)-1H-
indazole-3-carboxamide) – 27 September 2012 – 
Latvia
57.  AM-2201 indazolecarboxamide analogue (N-1-
naphthalenyl-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide – 30 October 2012 – Finland
27.  2,4,5-Trimethylmethcathinone / 2,4,5-TMMC 
(2-methylamino-1-(2,4,5-trimethylphenyl)propan-1-
one)) – 8 May 2012 – Germany 
28.  APINACA (N-(1-adamantyl)-1-pentyl-1H-indazole-3-
carboxamide) – 21 May 2012 – Bulgaria 
29.  5-IT (5-(2-aminopropyl)indole) – 1 June 2012 – 
Norway 
30.  Zopiclone (6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-
pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-
carboxylate) – 1 June 2012 – United Kingdom
31.  UR-144 (-2H) ([1-(pent-4-en-1-yl)-1H-indol-3-yl]
(2,2,3,3-tetramethylcyclopropyl)methanone) – 14 June 
2012 – France 
32.  25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-
methoxybenzyl)phenethylamine) – 21 June 2012 – 
Sweden
33.  4-HO-DPT (4-hydroxy-N,N-dipropyltryptamine) – 21 
June 2012 – Sweden
34.  5-MeO-MET (5-methoxy-N-ethyl-N-methyl-tryptamine) 
– 21 June 2012 – Sweden
35.  STS-135 (N-(1-adamantyl)-1-(5-fluoropentyl)-1H-
indole-3-carboxamide) – 26 June 2012 – Hungary
36.  MPHP (1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-hexan-1-
one) – 26 June 2012 – Sweden
37.  APICA (N-(1-adamantyl)-1-pentyl-1H-indole-3-
carboxamide) – 13 July 2012 – Finland
38.  JWH-018 carboxamide derivative (1-pentyl-N-
(naphthalen-1-yl)-1H-indole-3-carboxamide) – 16 July 
2012 – Finland 
39.  MDDM (3,4-methylenedioxy-N,N-
dimethylamphetamine) – 17 July 2012 – Austria
40.  MAM-2201 chloropentyl derivative 
([1-(5-chloropentyl)-1H-indol-3-yl](4-methyl-1-
naphthalenyl)methanone) – 18 July 2012 – United 
Kingdom
41.  JWH-122 pentenyl 2-methylindole derivative 
((4-methylnaphthalen-1-yl)[2-methyl-1-(pent-4-en-1-yl)-
1H-indol-3-yl)]methanone) – 18 July 2012 – United 
Kingdom
42.  JWH-122 pentenyl derivative ((4-methylnaphthalen-1-
yl)(1-(pent-4-en-1-yl)-1H-indol-3-yl)methanone) – 18 
July 2012 – United Kingdom
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65.  4-CA/4-chloroamphetamine (1-(4-chlorophenyl)
propan-2-amine) – 7 December 2012 – Hungary
66.  25B-NBOMe (2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine) – 6 December 2012 
– Sweden
67.  2C-G (1-(2,5-dimethoxy-3,4-dimethylphenyl)propan-2-
amine) – 6 December 2012 – Poland
68.  2C-N (2,5-dimethoxy-4-nitrophenethylamine) – 6 
December 2012 – Poland
69.  25E-NBOMe (2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine) – 6 December 
2012 – Poland
70.  25G-NBOMe (2-(2,5-dimethoxyphenyl-3,4-dimethyl)-
N-[(2-methoxyphenyl)methyl]ethanamine) – 6 
December 2012 – Poland
71.  25N-NBOMe (2-(2,5-dimethoxyphenyl-4-nitro)-N-[(2-
methoxyphenyl)methyl]ethanamine) – 6 December 
2012 – Poland
72.  4-Methylaminorex p-methyl derivative – 10 December 
2012 – the Netherlands
73.  4-Methylphendimetrazine – 12 December 2012 
– Poland
58.  JWH-018 carboxylate analogue, quinolinyl derivative 
(quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) – 20 
November 2012 – Finland
59.  AB-005 ([1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-
3-yl](2,2,3,3-tetramethylcyclopropyl)methanone) – 20 
November 2012 – Germany
60.  AB-005 azepane isomer ((1-(1-methylazepan-2-yl)-1H-
indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone) 
– 20 November 2012 – Germany
61.  4-HTMPIPO (4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-
indol-3-yl)pentan-1-one) – 30 November 2012 – 
Sweden
62.  (Iso)butyryl-F-fentanyl N-benzyl analogue (N-(1-
benzylpiperidin-4-yl)-N-(x-fluorophenyl)-butanamide) 
– 4 December 2012 – Finland
63.  (Iso)butyryl fentanyl (2-methyl-N-phenyl-N-[1-(1-
phenylpropan-2-yl)piperidin-4-yl]propanamide) – 4 
December 2012 – Finland
64.  UR-144 N-(5-chloropentyl) analogue 
((1-(5-chloropentyl)-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)methanone) – 7 
December 2012 – Hungary
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Annex 2.  New psychoactive substances in the category of miscellaneous ‘others’ that were 
notified to the EMCDDA and Europol for the first time in 2012 under the terms of 
Council Decision 2005/387/JHA
Name Annex 1 ref Type of substance
3-MeO-PCP
2-MeO-ketamine
N-ethylnorketamine
21
50
53
Aminocyclohexanes
Zopilcone
Pyrazolam
30
49
Medicinal products
5-APDI 54 Arylethylamine (indenyl derivative of an aminoalkylbenzofuran)
5-APDB
6-APDB
15
17
Arylethylamine (aminoalkylbenzofuran)
4-Methylphendimetrizine 73 Derivative of a medicinal product 
ECX 19 Alkynyl cyclohexanol
4-Methylaminorex p-methyl derivative 72 Derivative of a withdrawn medicinal product
Thienoamphetamine 13 Arylethylamine (thiophene derivative of amphetamine)
AH-7921 47 Narcotic analgesic (cyclohexylmethylbenzamide)
Phenibut 16 Derivative of gamma-amino butyric acid
4-Fluoroephedrine 20 Derivative of ephedrine
(Iso)butyryl fentanyl 63 Narcotic analgesic (derivative of fentanyl)
5-IT 29 Substituted indole
1-Cyclohexyl-x-methoxybenzene
(Iso)butyryl-F-fentanyl N-benzyl analogue
9
62
Potential intermediates or precursors of other drugs
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New psychoactive substance (Council Decision 
2005/387/JHA)
Council Decision 2005/387/JHA broadened the scope of, 
and replaced, the 1997 Joint Action. Like the Joint Action, it 
takes the United Nations drug control Conventions as a 
point of reference, both to define the scope of the Council 
Decision (Article 2) and for the definition of a new 
psychoactive substance (Article 3). 
Council Decision 2005/387/JHA (57) defines a new 
psychoactive substance as ‘a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation, that has 
not been scheduled under the 1961 United Nations Single 
Convention on Narcotic Drugs, and that may pose a threat 
to public health comparable to the substances listed in 
Schedule I, II or IV’ (new narcotic drug) or ‘under the 1971 
United Nations Convention on Psychotropic Substances, 
and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV’ (new 
psychotropic drug). A preparation is defined as ‘a mixture 
containing a new psychoactive substance’ (Article 3).
The wording of this definition has a number of implications, 
for example, substances already listed under the UN 
Conventions are by definition excluded from the scope of 
the Council Decision. An important difference to the 1997 
Joint Action is the inclusion of narcotic drugs (1961 UN 
Convention) and psychotropic substances which pose a 
comparable threat as substances listed in Schedules III or 
IV of the 1971 UN Convention.
‘This Decision relates to end-products, as distinct from 
precursors in respect of which Council Regulation (EEC) No 
3677/90 of 13 December 1990 laying down measures to 
be taken to discourage the diversion of certain substances 
to the illicit manufacture of narcotic drugs and psychotropic 
substances (58), and Regulation (EC) No 273/2004 of the 
The Joint Action 97/396/JHA and the Council Decision 
2005/387/JHA provide legally binding definitions of the 
substances they cover; however, there are a number of 
other terms in common usage in this area which may cause 
confusion. For example, at least historically, new 
psychoactive substances have often been referred to as 
‘designer drugs’ although today the term ‘legal highs’ is 
used more often. Much overlap exists between these terms 
but for practical purposes it is worth delineating the 
concepts.
The term ‘new’ in all definitions is not intended to refer 
exclusively to newly invented or newly synthesised 
substances, but rather should be understood as ‘newly 
available’ or ‘newly misused’. 
New synthetic drug (Joint Action 97/396/JHA)
The 1997 Joint Action 97/396/JHA (53) concerned new 
synthetic drugs ‘which are not currently listed in any of the 
Schedules to the 1971 United Nations Convention on 
Psychotropic Substances (54), and which pose a 
comparable serious threat to public health as the 
substances listed in Schedules I or II thereto and which 
have a limited therapeutic value’ (Article 2). 
The Joint Action ‘relates to end-products, as distinct from 
precursors in respect of which Council Regulation (EEC) No 
3677/90 of 13 December 1990 laying down measures to 
be taken to discourage the diversion of certain substances 
to the illicit manufacture of narcotic drugs and psychotropic 
substances (55) and Council Directive 92/109/EEC of 14 
December 1992 on the manufacture and the placing on the 
market of certain substances used in the illicit manufacture 
of narcotic drugs and psychotropic substances (56) provide 
for a Community regime’ (Article 2).
(53)  Joint Action 97/396/JHA of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty on European Union, concerning the 
information exchange, risk assessment and the control of new synthetic drugs. OJ L 167, 25.06.1997, p. 1.
(54)  1971 United Nations Convention on Psychotropic Substances.
(55)  Council Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken to discourage the diversion of certain 
substances to the illicit manufacture of narcotic drugs and psychotropic substances. OJ L 357, 20.12.1990, p. 1. Regulation as last amended 
by Commission Regulation (EEC) No 3769/92 (OJ L 383, 29. 12. 1992, p. 17).
(56)  Council Directive 92/109/EEC of 14 December 1992 on the manufacture and the placing on the market of certain substances used in the 
illicit manufacture of narcotic drugs and psychotropic substances. OJ L 370, 19.12.1992, p. 76. Directive as amended by Directive 93/46/EEC 
(OJ L 159, 1. 7. 1993, p. 134).
(57)  Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances, 
OJ L 127, 20.5.2005, p. 32.
(58)  OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1232/2002 (OJ L 180, 10.7.2002, p. 5).
Annex 3.  Legal and working definitions used by the EMCDDA to classify  
and describe new drugs
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market, while others, the so-called ‘legal highs’, are sold 
more openly. A further development to this phenomenon is 
the detection of non-controlled psychoactive medicines on 
the market. The way in which some of these new drugs are 
marketed and distributed is also becoming more 
sophisticated. This includes their advertisement and sale on 
the open market, such as through the Internet (with delivery 
via courier and postal services), as well as sale in ‘bricks 
and mortar’ head shops.
‘Designer drugs’
The way in which new drugs are produced, marketed and 
supplied can differ significantly. Some are sold directly on 
the illicit drug market. Here, they may be produced from 
chemical precursors in illicit production facilities of varying 
size and sophistication. In the past, these have typically 
been referred to as ‘designer drugs’ (62) — drugs that are 
intentionally designed to mimic the effects of controlled 
drugs but by slightly altering their chemical structure they 
circumvent existing controls. Examples include PMMA 
(para-methoxyamphetamine) and 2C-I (2,5-dimethoxy-4-
iodophenethylamine), which are now controlled across the 
EU because of the harm they pose. New drugs sold on this 
market may also be tableted or otherwise packaged from 
bulk substances that are bought from legitimate sources; 
these include mCPP and BZP. 
Both precursors and the substances themselves have been 
sourced from third countries and from within Europe. This 
market is dynamic, with source countries changing over 
time and place. While the source countries for precursors 
are often unclear, in some cases, the precursor is offered for 
sale on the Internet by chemical suppliers that appear to be 
based in China.
Overall, these new drugs are believed to be largely used 
surreptitiously by producers as replacements for 
established controlled drugs which may be in short supply, 
such as MDMA (ecstasy). This supposition is supported by 
the finding that many of them are found as tablets that use 
the same logos as ecstasy tablets. In some cases, new 
drugs may also be found in combination with controlled 
drugs, possibly in an attempt to ‘bulk up’ the drug and 
thereby reduce the amount of controlled drug. An example 
of both uses is the identification in 2004 of the piperazine 
European Parliament and of the Council of 11 February 
2004 on drug precursors (59) provide for a Community 
regime’ (Article 2).
‘The new psychoactive substances covered by this Decision 
may include medicinal products as defined in Directive 
2001/82/EC of the European Parliament and of the Council 
of 6 November 2001 on the Community Code relating to 
veterinary medicinal products (60) and in Directive 
2001/83/EC of the European Parliament and of the Council 
of 6 November 2001 on the Community Code relating to 
medicinal products for human use (61)’ (point 5 of the recital 
to the Council Decision). However, ‘substances of 
established and acknowledged medical value are therefore 
excluded from control measures based on this Decision’ 
(point 8 of the recital to the Council Decision) as are 
psychoactive substances used to manufacture a medicinal 
product (Article 7.3).
New drugs
New psychoactive substances (new drugs) make up a 
broad range of substances that are not controlled under 
international drug laws. Often they are intended to mimic 
the effects of existing controlled drugs. This is reflected in 
the fact that many are chemically similar to controlled 
drugs, but, at the same time, sufficiently different that they 
fall outside of the scope of drug laws. In addition, a growing 
number of new substances from entirely different chemical 
families, including stimulants and substances that mimic 
the effects of cannabis or opioids, have also recently been 
detected.
The term ‘new’ refers to the fact that these substances are 
new to the drug market or newly misused. Many new drugs 
have previously been described in the scientific and patent 
literature as part of legitimate research and development. 
Some have been used in experiments designed to better 
understand the complex signalling pathways in our bodies, 
while others have been studied as potential medicines. 
However, a common feature is that there is usually limited 
information about the effects of these drugs in humans and 
the harms that they may cause. Nonetheless, it appears 
that those involved in supplying new substances are 
increasingly searching this literature for potential new 
drugs. Some of these are then sold directly on the illicit 
(59)  OJ L 47, 18.2.2004, p. 1.
(60)  OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).
(61)  OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).
(62)  The term ‘designer drugs’ emerged in the 1980s in relation to some novel fentanyl compounds and became particularly popular with the 
emergence of the ‘ecstasy’ compounds (MDMA, MDA, MDE, etc) on the illicit drug market, although strictly speaking these drugs were around 
long before the term ‘designer drug’ became popular.
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and packaging of these substances have also been seized 
within the EU.
As part of the marketing strategy to offer a replacement for 
controlled drugs, distributors and retailers may use names 
for ‘legal high’ products that allude to, or sound like, 
controlled drugs: ‘Snow blow’ for cocaine or ‘Xtacy’ and 
‘Doves Red’ (63) for MDMA. Common street names of 
controlled drugs are also used (e.g. calling products 
‘Charlie’, which is also a street name for cocaine). There 
have also been attempts to deceive consumers by 
marketing synthetic drugs as ‘natural’ herbal products, such 
as in the case of ‘Spice’ products that contained synthetic 
cannabinoids. In the majority of such cases, the substances 
are not listed on the product packaging. It is also clear that 
retailers are exploiting the Internet as a vehicle for the 
marketing and sale of ‘legal highs’. 
Importantly, some online shops sell not only retail products 
but also bulk quantities of substances, presumably for 
resale. In order to raise the profile of their products, Internet 
retailers use a range of marketing techniques. Many focus 
around selling the idea that ‘legal highs’ are good 
replacements for controlled drugs. Social media are also 
used a marketing tool. This includes posting videos on 
YouTube of ‘real people’ using the drugs and reviewing their 
effects. Some of these are set at music festivals, where 
traditionally the use of illicit drugs is common. In some 
cases, these videos are shot as ‘before’ and ‘after’ reviews 
to emphasise the effects of the drugs.
The ‘legal highs’ market is characterised by the speed at 
which suppliers circumvent drug controls by offering new 
alternatives to restricted products and advertising them 
with modern marketing strategies.
Finally, the term ‘legal highs’ is often used to refer to the 
phenomenon, rather than to a specific substance, similarly 
to the ‘Spice’ phenomenon, which is used to describe the 
marketing and sale of herbal products containing synthetic 
cannabinoid receptor agonists.
A further dimension of the new drug phenomenon is the 
growing number of psychoactive medicines that are being 
misused. Some of these are authorised as medicinal 
products within the EU (such as pregabalin) and are either 
diverted from the regulated market or imported from third 
countries. They may also include substances and products 
that are not licensed within the EU, such as phenazepam 
and etizolam (benzodiazepines).
derivative mCPP in tablets sold as ecstasy. One possible 
reason for the emergence of mCPP was the decreased 
availability of the chemical precursors used in the synthesis 
of MDMA. This, coupled with the fact that mCPP appears to 
mimic some of the subjective effects of MDMA and that it 
could be legally sourced in Europe and elsewhere, may have 
made it an attractive substitute to producers. Similarly, 
although BZP came to prominence as ‘party pills’, and was 
commonly sold on the open ‘legal highs’ market as such, 
some of the tablets that were seized on the illicit market 
were clearly intended to be sold as ecstasy, bearing typical 
ecstasy logos. It is also important to note that some of 
these new substances are also sold as drugs in their own 
right (e.g. 2C-B, also known as ‘Nexus’, which is now under 
international control) or as a ‘special type’ of ecstasy (such 
as mCPP).
‘Legal highs’
Another group of new psychoactive substances — the 
so-called ‘legal highs’ — are legally sourced and sold as 
replacements for controlled drugs on the open market by 
exploiting existing laws. This group includes a wide range of 
synthetic and plant-derived substances that are often sold 
as branded products. They are also sometimes sold in 
combination with other new substances. This may be an 
attempt to better mimic the effects of controlled drugs, or 
to achieve novel psychoactive effects, or as a result of 
accidental contamination or deliberate substitution. These 
so-called ‘legal highs’ are usually sold through the Internet 
and in ‘bricks and mortar’ head shops. They may also be 
sold by street-level drug dealers. Mostly, they are advertised 
with aggressive and innovative marketing strategies. Often, 
in order to disguise the fact that they are psychoactive 
drugs, and circumvent ‘grey areas’ in consumer protection 
and marketing regulations, they are sold under various 
product labels, including ‘research chemicals’, ‘bath salts’ 
and ‘plant food’, and usually with an accompanying 
disclaimer that they are not intended for human 
consumption. However, describing these substances as 
‘legal’ may not be strictly correct, as some may be regulated 
by medicines, food safety or other consumer protection 
laws; some may even contain controlled drugs.
Information from border seizures and law enforcement 
investigations in the EU Member States indicate that 
substances sold as ‘legal highs’ are typically imported, 
sometimes in multi-kilogram quantities, from China and, to 
a lesser degree, India. Moreover, facilities for the processing 
(63)  ‘Doves’ is a street name for ecstasy.
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•  Piperazines are represented by mCPP (1-(3-chlorophenyl)
piperazine) and BZP (1-benzylpiperazine), both of which 
are stimulants.
•  Cathinones have stimulant effects. The main cathinone 
derivatives are the semi-synthetic methcathinone and the 
synthetic compounds mephedrone, methylone and 
MDPV (3,4-methylenedioxypyrovalerone).
•  Synthetic cannabinoids share some functional similarities 
with Δ9-tetrahydrocannabinol (THC), the active principle 
of cannabis. Like THC, they can have sedative, depressant 
and hallucinogenic effects. They have been detected in 
herbal smoking mixtures such as ‘Spice’ as well as resins 
that mimic cannabis resin.
•  Other substances reported to the EWS include various 
plant-derived and synthetic psychoactive substances 
(e.g. indanes, benzodifuranyls, narcotic analgesics, 
synthetic cocaine derivatives, ketamine and 
phencyclidine derivatives), which do not strictly belong to 
any of the previous families. Also included here are a 
number of medicinal products and derivatives.
It is scientifically sound practice to categorise new 
psychoactive substances based on their chemical structure 
(i.e. by chemical families, see table below). Exceptions to 
this are the group of synthetic cannabinoids, which are 
currently categorised based on their mode of action and the 
group of miscellaneous ‘others’ (section 3.1.6). Described 
below are the main families of psychoactive substances 
notified through the EU Early warning system (EWS) to 
date. For further details on these categories see the 
EMCDDA drug profiles (64).
•  Phenethylamines encompass a wide range of substances 
that may exhibit stimulant, entactogenic or hallucinogenic 
effects. Examples include the synthetic substances 
amphetamine, methamphetamine, MDMA 
(3,4-methylenedioxymethamphetamine) and mescaline 
(the latter of which occurs naturally).
•  Tryptamines include a number of substances that have 
predominantly hallucinogenic effects. The main 
representatives are the naturally occurring compounds 
dimethyltryptamine (DMT), psilocin and psilocybin (found 
in hallucinogenic mushrooms) as well as the semi-
synthetic lysergic acid diethylamide (LSD).
Annex 4.  Main groups of new psychoactive substances monitored by  
the EU Early warning system
(64) Available at: http://www.emcdda.europa.eu/publications/drug-profiles 
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About this report
The unprecedented growth in the number, type and availability of new drugs over the past 
few years has seen the phenomenon take on global significance. Overall, the number of 
substances notified in the last two years accounts for more than half of the total number of 
substances notified to the EU Early warning system since May 2005. Driven by globalisation, 
technological advancement and the Internet, an open market for new drugs has now 
developed which presents challenges to public health, law enforcement and policy making. 
The rapid appearance of non-controlled alternatives to controlled drugs underlines the ability 
of the market to respond to changes in the legal status of psychoactive substances and has 
been accompanied, in some cases, by serious adverse health consequences. It is well 
established that organised crime is involved in some of these activities and continues to 
exploit the opportunities presented by the market in new drugs. This report presents the key 
activities performed by the EMCDDA and Europol in 2012 and includes details of all the 
relevant activities in support of the implementation of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new psychoactive substances.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the hub of drug-related 
information in Europe. Its mission is to provide the EU 
and its Member States with ‘factual, objective, 
reliable and comparable information’ on drugs, drug 
addiction and their consequences. Established in 
1993, it opened its doors in Lisbon in 1995 and is 
one of the EU’s decentralised agencies. With a strong 
multidisciplinary team, the agency offers 
policymakers the evidence base they need for 
drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice 
and new areas for analysis. As well as gathering 
information on the demand and reduction of the 
demand for drugs, the agency in recent years has 
extended its monitoring and reporting on drug 
supply, supply reduction and illicit drug markets.
www.emcdda.europa.eu
About Europol
Europol is the European Union’s law enforcement 
agency. Its aim is to improve the effectiveness of, and 
cooperation between, the competent authorities in 
the EU Member States in preventing and combating 
serious international organised crime and terrorism. 
Operational since 1999 and based in The Hague, the 
organisation employs some 600 staff to support 
national law-enforcement agencies in their everyday 
work, including efforts to tackle illicit drug trafficking, 
money laundering, cyber crime and terrorism. 
Europol comes into play when an organised criminal 
structure is involved and two or more EU Member 
States are affected. Among others, it facilitates 
cross-country information exchange and provides 
analysis of operations.
www.europol.europa.eu
